

Prof. OSMAN İLHAN



Personal Information

Email: osman.ilhan@lokmanhekim.edu.tr

Other Email: osmanilhandr@gmail.com

Web: <https://avesis.lokmanhekim.edu.tr/osman.ilhan>

International Researcher IDs


ScholarID: FceJ7VkAAAAJ

ORCID: 0000-0003-1665-372X

Publons / Web Of Science ResearcherID: ABC-8182-2021

ScopusID: 7005816382

Yoksis Researcher ID: 172878



Education Information

Post Doctorate of Medicine, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü,
Turkey 1988 - 1990

Expertise In Medicine, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü,
Turkey 1978 - 1983

Undergraduate, Ankara University, Tıp Fakültesi, Turkey 1972 - 1978

Biography

1978 yılında Ankara Tıp Fakültesinden mezun oldu. Aynı fakültede 1982 yılında İç Hastalıkları Uzmanlığını aldıktan sonra, askerlik görevini GATA Hematoloji Kliniğinde başasistan olarak yaptı. Mecburi Hizmet görevini SSK Ulus hastanesinde tamamladıktan sonra yan dal ihtisası için AÜTF' ne döndü.

1991 yılında Hematoloji doçenti oldu. Lösemi konusunda bilgi ve görgüsünü arttırmak için İtalya Cenova'da çalıştı. Türkiye'de ilk defa yapılan kandan kök hücre nakli ekibinde görev aldı. Türk ALL çalışma grubu başkanlığını yapan Dr. İlhan 1993-96 yıllarında AÜTF yönetim kurulu üyeliği yaptı.

1996 yılında ABD'de giderek M.D.Anderson Cancer Center' de Prof. Dr. Martin Korbling ve Prof. Dr. Richard Champlin' le Kök Hücre Mobilizasyonu Kriyoprezervasyonu ve Nakil konularında çalıştı.

1996 yılında Hematoloji profesörü oldu.

1999 yılında ESFH (European Society for Hemapheresis) bölge başkanı seçildi. 2000 yılında Hemaferes Derneği Kurucu Başkanı olan Dr. İlhan 2001'de World Apheresis Association (WAA) yönetimine girdi.

2001 yılı Ekim ayında Türk Hematoloji Derneği Başkanı oldu. İki dönem başkanlığı takiben 2005 yılında Dünya Hematoloji Kongre başkanı iken kendi isteği ile ayrıldı.

Halen başkanlığını yaptığı Türkiye Kemik İliği Transplantasyon Vakfında değişik görevler aldı.

Avrupa Hematoloji Birliği'nda (EHA) aktif görev yapan Dr. İlhan eğitim ile ilgili ECAH' ın (European Committee in Accreditation of Hematology) kurul üyeliği yaptı.

Provider Status olarak da Türkiye'de yapılan kongre ve kursların akreditasyonunda rol alarak CME kredilenmesinde Türk Hematologların önünü açtı.

JACIE (Joint Accreditation Committee ISCT-EBMT) müfettişi olan Dr. İlhan aynı zamanda Türkiye sorumlusu oldu.

MDS Foundation üyesi olan Dr. İlhan, 2005 yılında 30. ISH Dünya Hematoloji Kongresini İstanbul'da, 15. ESFH Avrupa Aferez Kongresini Antalya'da başkanlığını yaparak ilklere imzasını attı.

Balkan Hematoloji Birliği'nin kurulmasında önemli rol oynayan Dr. İlhan 2003-2006 yılları arasında Ankara Tıp Fakültesi Hematoloji Bilim Dalı Başkanlığı süresinde kliniği uluslararası standartlara getirmeye çalıştı.

2008 yılında kurulan Hücresel Tedavi ve Rejeneratif Tıp Derneğinde kurucu başkan olarak görev aldı.

2011 yılında Geriatrik Hematoloji Derneğinde kurucu başkanı oldu.

2012'de yapılan Dünya Aferez Kongresi (WAA)Onursal Başkanıdır.

Sağlık Bakanlığı'nda daha önce ilaç ruhsatlandırma ve etik kurullarında görev alan Dr. İlhan, Fotoferez-Aferez Komisyonu Başkanlığı, Kemik İliği Nakli Bilimsel Kurul Başkanlığı yanı sıra Ulusal Organ Doku Hücre Koordinasyon Kurulu Başkanlığı'nı, Kordon Kanı Bilimsel Kurulu ve Kök Hücre Araştırma Kurulu Başkanlığı yapmıştır.

KÖK HÜCRE VAKFI kurucu başkanıdır. Türkiye'nin kemik iliği ve kök hücre naklinde uluslararası düzeye gelmesinde katkıda bulunmuştur.

TÜRKÖK (Türkiye Kök Hücre Verici Bankası) kurulmasında önemli rol almıştır.

500'den fazla Pub-Med' de kayıtlı dergilerde yayını bulunan Dr. İlhan, 6150'den fazla atıf vardır. H Faktörü 35' tir. 1050 Avrupa Hematoloji Birliği Sürekli Tıp Eğitimi (EHA-CME) kredisi vardır.

Avrupa Hematoloji Birliğinin Platin CME sertifikasının sahibidir.

Transfusion and Scienceve Therapeutic Apheresis dergilerinin editorial board üyesidir.

Avrupa Kan ve Kemik İliği Nakli Birliği'nden (EBMT-JACIE) hizmet ödülü almıştır. Yine bu alanda Türk Hematoloji Derneği tarafından teşekkür belgesi sahibidir.

Hemaferez Derneğinin "Hayat Boyu Hizmet Ödülü"nün sahibi olan Prof. Dr. Osman İlhan adına 2009 yılından itibaren her yıl dernek tarafından "Prof. Dr. Osman İlhan Hemaferez Ödülü" bir araştırmacıya verilmektedir.

KÖKTEN ÇÖZÜM, HEMAFEREZ, KANSER KÖK HÜCRESİ ve TELE HEMATOLOJİ alanında kendi adına Türk Patent Enstitüsü'nden marka patenti almıştır.

Ankara Tıplılar Vakfı Başkanlığını yapan Prof. Dr. Osman İlhan halen Ankara Tıplılar Derneği Başkanlığına devam etmektedir.

Foreign Languages

English, C1 Advanced

Research Areas

Health Sciences

Academic Titles / Tasks

Professor, Lokman Hekim University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2024 - Continues

Professor, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 1978 - 2023

Academic and Administrative Experience

Academic Council Member of Department, Lokman Hekim University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2024 - Continues

Head of Department, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2021 - 2022

Head of Department, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2019 - 2022

Head of Department, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2003 - 2006

Head of Department, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 1993 - 1996

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey**
Lahmer T., Salmanton-García J., Marchesi F., El-Ashwah S., Nucci M., Besson C., Itri F., Jaksic O., Čolović N., Weinbergerová B., et al.
Infection, vol.52, no.3, pp.1125-1141, 2024 (SCI-Expanded)
- II. **The effect of danger-associated molecular patterns on survival in acute graft versus host disease**
Çelik S., KAYNAR L., Güven Z. T., Atasever Duran K., KONTAŞ O., KEKLİK M., ÜNAL A.
Bone Marrow Transplantation, vol.59, no.2, pp.189-195, 2024 (SCI-Expanded)
- III. **Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry**
Musto P., Salmanton-García J., Sgherza N., Bergantim R., Farina F., Glenthøj A., Cengiz Seval G., Weinbergerová B., Bonuomo V., Bilgin Y. M., et al.
Hematological Oncology, vol.42, no.1, 2024 (SCI-Expanded)
- IV. **Stem cell mobilizing effect of heparin in patients undergoing autologous stem cell transplantation**
Merter M., Sahin U., İLHAN ., Beksac M.
Journal of Clinical Apheresis, vol.38, no.6, pp.685-693, 2023 (SCI-Expanded)
- V. **Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings**
Rossi G., Salmanton-García J., Cattaneo C., Marchesi F., Dávila-Valls J., Martín-Pérez S., Itri F., López-García A., Glenthøj A., da Silva M. G., et al.
International Journal of Infectious Diseases, vol.137, pp.98-110, 2023 (SCI-Expanded)
- VI. **The world apheresis association registry, 2023 update**
Vrieling H., Le Poole K., Stegmayr B., Kielstein J., Berlin G., İLHAN ., CENGİZ SEVAL G., Prophet H., Aandahl A., Deeren D., et al.
Transfusion and Apheresis Science, vol.62, no.6, 2023 (SCI-Expanded)
- VII. **Unmet clinical needs and challenges in the management of acute leukemia in Turkey: a modified Delphi study**
Arat M., Alacacioglu I., Bolaman A. Z., Buyukasik Y., Cagirgan S., Güvenc B., Kaya E., Ozcan M. A., Salim O., Vural F., et al.
Future Oncology, vol.19, no.14, pp.975-982, 2023 (SCI-Expanded)
- VIII. **Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome**

Beksac M., CENGİZ SEVAL G., Koyun D., TOPÇUOĞLU P., YÜKSEL M., Gurman G., İlhan O.

Clinical Lymphoma, Myeloma and Leukemia, vol.23, no.3, 2023 (SCI-Expanded)

- IX. **Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry**
Busca A., Salmanton-García J., Marchesi F., Farina F., Seval G. C., Van Doesum J., De Jonge N., Bahr N. C., Maertens J., Meletiadis J., et al.
Frontiers in Immunology, vol.14, 2023 (SCI-Expanded)
- X. **Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center**
CENGİZ SEVAL G., Bozdağ S. C., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., DEMİRER T., Gurman G., Beksac M., İlhan O., et al.
Balkan Medical Journal, vol.40, no.3, pp.197-204, 2023 (SCI-Expanded)
- XI. **Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data**
Kırcalı E., Seval G. C., Öztürk C., Yılmaz H., Koyun D., Bozdağ S. C., Toprak S. K., Topçuoğlu P., Arslan Ö., Özcan M., et al.
Balkan Medical Journal, vol.40, no.1, pp.51-56, 2023 (SCI-Expanded)
- XII. **Prognostic factors in thrombotic thrombocytopenic purpura**
Yalçın M., İlhan O.
Turkish Journal of Biochemistry, vol.47, no.5, pp.626-632, 2022 (SCI-Expanded)
- XIII. **Gemcitabine, Cisplatin, and Dexamethasone as a Salvage and Mobilization Chemotherapy Before Autologous Stem Cell Transplantation is Effective and Safe Outpatient Regimen in Relapsed and Refractory Hodgkin Lymphoma Patients**
Gokmen A., Sahin U., Soydan E., Gokgoz Z., Okcu M. K., Ozan U., ARSLAN Ö., İlhan O., ÖZCAN M.
Clinical Lymphoma, Myeloma and Leukemia, vol.22, no.10, 2022 (SCI-Expanded)
- XIV. **Effect of CD34+ Total/Myeloid CD34+ Cell Progenitors and B-Lymphoid Progenitors Within the Bone Marrow Grafts on the Hematopoietic Recovery After Hematopoietic Stem Cell Transplantation**
DALVA K., HASKOLOĞLU Z. Ş., DALVA AYDEMİR S., Oz M. D., ÖZTÜRK BİRGE A., Ipek S., Demir H. A., ERTEM M., İLHAN ., Gurman G.
Experimental and Clinical Transplantation, vol.20, no.10, pp.937-944, 2022 (SCI-Expanded)
- XV. **Pretransplant Consolidation Therapies Improve the Outcome of Myeloablative Allogeneic Transplantation in Adults with Ph-negative Acute Lymphoblastic Leukemia**
Ozdemir Z. N., Kırcalı E., Şahin U., Seval G. C., Bozdağ S. C., Toprak S. K., Yuksel M. K., Topcuoglu P., Arslan O., Demirer T., et al.
Clinical Lymphoma, Myeloma and Leukemia, vol.22, no.8, pp.596-600, 2022 (SCI-Expanded)
- XVI. **COVID-19 and hairy-cell leukemia: An EPICOVIDEHA survey**
Lamure S., Salmanton-García J., Robin-Marieton E., Jaksic O., Kohn M., Marchesi F., Marchetti M., El-Ashwah S., Demirkan F., Valković T., et al.
Blood Advances, vol.6, no.13, pp.3870-3874, 2022 (SCI-Expanded)
- XVII. **Alpha-1-Antitrypsin Experience for Steroid-Resistant Acute Graft-Versus-Host Disease**
Koyun D., CENGİZ SEVAL G., Kırcalı E., Bozdağ S. C., TOPRAK S. K., TOPÇUOĞLU P., ÖZCAN M., ARSLAN Ö., DEMİRER T., İLHAN ., et al.
Indian Journal of Hematology and Blood Transfusion, vol.38, no.3, pp.601-605, 2022 (SCI-Expanded)
- XVIII. **Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study**
Soran H., Freiburger T., Harada-Shiba M., Cuchel M., Tromp T. R., Tromp T. R., Hartgers M. L., Hartgers M. L., Hovingh G. K., Hovingh G. K., et al.
The Lancet, vol.399, no.10326, pp.719-728, 2022 (SCI-Expanded)
- XIX. **Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial**
Garcia-Manero G., Mufti G. J., Fenaux P., Buckstein R., Santini V., Díez-Campelo M., Finelli C., İLHAN ., Sekeres M. A., Zeidan A. M., et al.

Blood, vol.139, no.4, pp.624-629, 2022 (SCI-Expanded)

- XX. **Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies COVID-19 Geçiren Türk Hematolojik Malignite Hastalarının Klinik Özellikleri ve Sonuçları**
Bozdağ S. C., Seval G. C., Hindilerden İ. Y., Hindilerden F., Andıç N., Baydar M., Kaynar L. A., Toprak S. K., Göksoy H. S., Aydın B. B., et al.
Turkish Journal of Hematology, vol.39, no.1, pp.43-54, 2022 (SCI-Expanded)
- XXI. **COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)**
Pagano L., Salmanton-García J., Marchesi F., Busca A., Corradini P., Hoenigl M., Klimko N., Koehler P., Pagliuca A., Passamonti F., et al.
Journal of Hematology and Oncology, vol.14, no.1, 2021 (SCI-Expanded)
- XXII. **Leukemic stem cells shall be searched in the bone marrow before “tyrosine kinase inhibitor-discontinuation” in chronic myeloid leukemia**
İLHAN ., Narli Ozdemir Z., DALVA K., Arslan A., Okay Ozgeyik M., Ipek S., Saydam G., HAZNEDAROĞLU İ. C.
International Journal of Laboratory Hematology, vol.43, no.5, pp.1110-1116, 2021 (SCI-Expanded)
- XXIII. **Analysis of extracorporeal photopheresis within the frame of the WAA register**
Blaħa M., Gasova Z., Berlin G., Audzijaoniene J., Griskevicius A., Dykes J., Bhuiyanova Z., Lanska M., Eich T., Vrieling H., et al.
Transfusion and Apheresis Science, vol.60, no.5, 2021 (SCI-Expanded)
- XXIV. **Using the World Apheresis Association Registry Helps to Improve the Treatment Quality of Therapeutic Apheresis**
Stegmayr B., Newman E., Witt V., Derfler K., Leitner G., Eloit S., Dhondt A., Deeren D., Ptak J., Blaħa M., et al.
Transfusion Medicine and Hemotherapy, vol.48, no.4, pp.234-239, 2021 (SCI-Expanded)
- XXV. **Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study**
Stilgenbauer S., Bosch F., İLHAN ., Kisro J., Mahé B., Mikuskova E., Osmanov D., Reda G., Robinson S., Tausch E., et al.
British Journal of Haematology, vol.193, no.2, pp.325-338, 2021 (SCI-Expanded)
- XXVI. **Acute Kidney Injury Due to Leukemic Infiltration in a Patient with Chronic Lymphocytic Leukemia**
Şahin G. K., Kocabay H. E., Kiremitçi S., İlhan O., Keven K.
Turkish Journal of Hematology, vol.38, no.2, pp.167-168, 2021 (SCI-Expanded)
- XXVII. **Acute kidney injury due to leukemic infiltration in a patient with chronic lymphocytic leukemia Kronik lenfositik lösemide lösemik infiltrasyona baėlı akut böbrek yetmezliėi**
KUMRU G., Kocabay H. E., KİREMİTÇİ S., İLHAN ., KEVEN K.
Turkish Journal of Hematology, vol.38, no.2, pp.167-168, 2021 (SCI-Expanded)
- XXVIII. **Highlighting the prognostic importance of measurable residual disease among acute myeloid leukemia risk factors Akut myeloid lösemi risk faktörleri arasında ölçülebilir kalıntı hastalığın prognostik öneminin vurgulanması**
Özdemir Z. N., Şahin U., Dalva K., Baltacı M. A., Uslu A., Öztürk C., Seval G. C., Toprak S. K., Yüksel M. K., Topçuoėlu P., et al.
Turkish Journal of Hematology, vol.38, no.2, pp.111-118, 2021 (SCI-Expanded)
- XXIX. **Blastic Plasmacytoid Dendritic Cell Neoplasm: Single Center Experience on a Rare Hematological Malignancy**
Narli Ozdemir Z., Cengiz Seval G., Sahin U., Uslu A., Gunduz M., Civriz Bozdog S., Toprak S. K., Kurt Yuksel M., Topcuoglu P., Kuzu I., et al.
Indian Journal of Hematology and Blood Transfusion, vol.37, no.1, pp.67-75, 2021 (SCI-Expanded)
- XXX. **Thyroid dysfunctions in adult patients after allogeneic hematopoietic stem cell transplantation**
Ataca Atilla P., Akkus E., Atilla E., Gokmen N., Civriz Bozdog S., Kurt Yuksel M., Toprak S. K., Baskal N., Akan H., Demirer T., et al.
Clinical Transplantation, vol.34, no.10, 2020 (SCI-Expanded)

- XXXI. **Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma**
Beksac M., Aydın Y., Goker H., Turgut M., Besisik S. K., Cagirgan S., Tuğlular T., Vural F., Yagci M., Alacacioglu I., et al.
Clinical Lymphoma, Myeloma and Leukemia, vol.20, no.8, 2020 (SCI-Expanded)
- XXXII. **Effects of ABO incompatibility in allogeneic hematopoietic stem cell transplantation Effets de l'incompatibilité ABO pour l'allogreffe de cellules souches hématopoïétiques**
Ataca Atila P., Akkus E., Atila E., Gökmen İnan N., Civriz Bozdog S., Kocak Toprak S., Kurt Yuksel M., ÖZCAN M. E., DEMİRER T., İLHAN ., et al.
Transfusion Clinique et Biologique, vol.27, no.3, pp.115-121, 2020 (SCI-Expanded)
- XXXIII. **Mental status and physical activity in patients with homozygous familial hypercholesterolemia: A subgroup analysis of a nationwide survey (A-HIT1 registry)**
Kuman Tunçel Ö., Kayıkçoğlu M., Pırıldar Ş., Yılmaz M., Kaynar L., Aktan M., Durmuş R. B., Gökçe C., Temizhan A., Özcebe O. İ., et al.
Journal of Clinical Lipidology, vol.14, no.3, pp.361, 2020 (SCI-Expanded)
- XXXIV. **Luspatercept in patients with lower-risk myelodysplastic syndromes**
Fenaux P., Platzbecker U., Mufti G. J., Garcia-Manero G., Buckstein R., Santini V., Díez-Campelo M., Finelli C., Cazzola M., İLHAN ., et al.
New England Journal of Medicine, vol.382, no.2, pp.140-151, 2020 (SCI-Expanded)
- XXXV. **Who 2016 definition of chronic myeloid leukemia and tyrosine kinase inhibitors Kronik myeloid lösemi who 2016 tanımlaması ve tirozin kinaz inhibitörleri**
HAZNEDAROĞLU İ. C., KUZU I., İLHAN .
Turkish Journal of Hematology, vol.37, no.1, pp.42-47, 2020 (SCI-Expanded)
- XXXVI. **Study for the diagnostic screening of paroxysmal nocturnal hemoglobinuria in older patients with unexplained anemia and/or cytopenia**
Ozdemir Z. N., İLHAN ., Ozet G., Falay M., YENEREL M. N., Tuğlular T., Turgut M., GÜVENÇ B., ÜNAL A., Ayyıldız O., et al.
Clinical Laboratory, vol.66, no.9, pp.1709-1715, 2020 (SCI-Expanded)
- XXXVII. **Evaluation of health and quality of life in apheresis patients – data from the WAA register**
Goto J., Newman E., Witt V., Deeren D., Blaha M., Lanska M., Gasova Z., Bhuiyan-Ludvikova Z., Hrdlickova R., Ramlow W., et al.
Transfusion and Apheresis Science, vol.58, no.5, pp.641-644, 2019 (SCI-Expanded)
- XXXVIII. **Study for the diagnostic screening of paroxysmal nocturnal hemoglobinuria in Turkey: Prospective multicentric evaluation of suspected patients**
İLHAN ., Ozdemir Z. N., Ozet G., Falay M., Yenerel M., Tuğlular T., Turgut M., GÜVENÇ B., Unal A., Ayyıldız O., et al.
Transfusion and Apheresis Science, vol.58, no.5, pp.659-662, 2019 (SCI-Expanded)
- XXXIX. **Who 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors**
Haznedaroğlu İ. C., Kuzu I., İLHAN O.
TURKISH JOURNAL OF HAEMATOLOGY, 2019 (SCI-Expanded)
- XL. **Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis**
Dagnew A. F., İLHAN ., Lee W., Woszczyk D., Kwak J., Bowcock S., Sohn S. K., Rodriguez Macías G., Chiou T., Quiel D., et al.
The Lancet Infectious Diseases, vol.19, no.9, pp.988-1000, 2019 (SCI-Expanded)
- XLI. **A CD34+ Cell Enrichment Protocol of Hematopoietic Stem Cells in a Well-Established Quality Management System**
Kilic P., Bay M., Yildirim Y., Coskun O., Seker S., Baydin P., Ulker O. L., Parmaksiz M., Deniz G. C., Yilmazer A., et al.
Cells Tissues Organs, vol.207, no.1, pp.15-20, 2019 (SCI-Expanded)
- XLII. **Clinical management, psychosocial characteristics, and quality of life in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis in Turkey: Results of a nationwide survey (A-HIT1 registry)**
Kayıkçoğlu M., Kuman-Tunçel O., Pırıldar S., Yılmaz M., Kaynar L., Aktan M., Durmuş R. B., Gökçe C., Temizhan A.,

Özcebe O. I., et al.

Journal of Clinical Lipidology, vol.13, no.3, pp.455-467, 2019 (SCI-Expanded)

- XLIII. **Comparison of the methods evaluating post thawing viability of peripheral blood stem cell graft**
Varan H. D., BAY M., ÖZTÜRK BİRGE A., DALVA K., İLHAN .
Transfusion and Apheresis Science, vol.58, no.2, pp.192-195, 2019 (SCI-Expanded)
- XLIV. **Early initiation of extracorporeal photochemotherapy increases response for chronic graft versus host disease following steroid failure L'initiation précoce de la photochimiothérapie extracorporelle augmente la réponse pour la maladie chronique du greffon contre l'hôte après échec des stéroïdes**
Gunduz M., Atilla E., Atilla P., TOPÇUOĞLU P., İLHAN .
Transfusion Clinique et Biologique, vol.26, no.1, pp.32-37, 2019 (SCI-Expanded)
- XLV. **Evaluation of the results of MOTAKK hepatitis C virus RNA genotyping and hepatitis delta virus external quality assessment programs during 2015-2016**
Karatayli E., Soydemir E., Aksoy Z. B., Kizilpinar M., Koçak A. A., Karatayli S. C., Yurdcu E., Yildirim U., Güriz H., Bozdayi G., et al.
Turkish Journal of Gastroenterology, vol.30, no.11, pp.957-963, 2019 (SCI-Expanded)
- XLVI. **Promising utilization areas of therapeutic plasmapheresis in cardiovascular surgery practice**
Durdu M. S., Cakici M., Gumus F., Deniz G. C., Bozdog S. C., ÖZÇINAR E., DİKMEN N., İLHAN ., Ucanok K.
Transfusion and Apheresis Science, vol.57, no.6, pp.762-767, 2018 (SCI-Expanded)
- XLVII. **Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up**
Saydam G., Haznedaroglu I. C., Kaynar L., Yavuz A. S., Ali R., Guvenc B., Akay O. M., Baslar Z., Ozbek U., Sonmez M., et al.
Hematology, vol.23, no.10, pp.771-777, 2018 (SCI-Expanded)
- XLVIII. **What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)?**
Kayikcioglu M., Tokgozoglu L., Dogan V., Ceyhan C., Tuncez A., Kutlu M., Onrat E., Alici G., Akbulut M., Celik A., et al.
Atherosclerosis, vol.277, pp.341-346, 2018 (SCI-Expanded)
- XLIX. **Evaluation of 2015-2016 MOTAKK HBV DNA and HCV RNA external quality assessment national program results MOTAKK HBV DNA ve HCV RNA dış kalite kontrol ulusal programi 2015-2016 sonuçlarının değerlendirilmesi**
Karatayli E., Soydemir E., Aksoy Z. B., Kizilpinar M., Altay Koçak A., Karatayli S. C., Yurdcu E., Yildirim U., Güriz H., Bozdayi G., et al.
Mikrobiyoloji Bulteni, vol.52, no.4, pp.348-366, 2018 (SCI-Expanded)
- L. **Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study**
Stilgenbauer S., Leblond V., Foà R., Böttcher S., İLHAN ., Knauf W., Mikuskova E., Renner C., Tausch E., Woszczyk D., et al.
Leukemia, vol.32, no.8, pp.1778-1786, 2018 (SCI-Expanded)
- LI. **JACIE: A 20 year-old voluntary body functioning worldwide**
YÜKSEL M., İLHAN .
Transfusion and Apheresis Science, vol.57, no.2, pp.153-158, 2018 (SCI-Expanded)
- LII. **Editorial**
İLHAN .
Transfusion and Apheresis Science, vol.57, no.2, pp.150, 2018 (SCI-Expanded)
- LIII. **Biography**
İLHAN .
Transfusion and Apheresis Science, vol.57, no.2, pp.151, 2018 (SCI-Expanded)
- LIV. **Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: Primary analysis of the randomized, open-label mable study**
Michallet A., Aktan M., Hiddemann W., İLHAN ., Johansson P., Laribi K., Meddeb B., Moreno C., Raposo J., Schuh A., et al.
Haematologica, vol.103, no.4, pp.698-706, 2018 (SCI-Expanded)

- LV. A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry)**
Kayikcioglu M., Tokgozoglu L., Yilmaz M., Kaynar L., Aktan M., Durmuş R. B., Gokce C., Temizhan A., Ozcebe O. I., Akyol T. K., et al.
Atherosclerosis, vol.270, pp.42-48, 2018 (SCI-Expanded)
- LVI. Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?**
Atilla E., Yalciner M., Atilla P. A., Ates C., Bozdog S. C., Yuksel M. K., Toprak S. K., Gunduz M., Ozen M., Akan H., et al.
Antiviral Therapy, vol.23, no.8, pp.647-653, 2018 (SCI-Expanded)
- LVII. Upper respiratory viral infections in patients with haematological malignancies after allogeneic haematopoietic stem cell transplantation: A retrospective study**
Atilla E., Sahin D., Atilla P. A., DOLAPÇI G. İ., TEKELİ F. A., Bozdog S. C., YÜKSEL M., TOPRAK S. K., İLHAN ., ARSLAN Ö., et al.
Antiviral Therapy, vol.23, no.6, pp.523-527, 2018 (SCI-Expanded)
- LVIII. DICER1 gene and miRNA dysregulation in mesenchymal stem cells of patients with myelodysplastic syndrome and acute myeloblastic leukemia**
Ozdogan H., GÜR DEDEOĞLU B., Oztemur Islakoglu Y., Aydos A., KÖSE S., ATALAY A., YEGİN Z. A., Avcu F., Ocean Cetinkaya D., İLHAN .
Leukemia Research, vol.63, pp.62-71, 2017 (SCI-Expanded)
- LIX. Extracorporeal photochemotherapy in mycosis fungoides Photochimiothérapie extracorporelle dans les mycoses fongiques**
Atilla E., Atilla P., Bozdog S., Yuksel M., Toprak S., Topcuoglu P., Akay B., Sanli H., Akan H., Demirer T., et al.
Transfusion Clinique et Biologique, vol.24, no.4, pp.454-457, 2017 (SCI-Expanded)
- LX. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: The randomized MabEase study**
Lugtenburg P., Avivi I., Berenschot H., İLHAN ., Marolleau J. P., Nagler A., Rueda A., Tani M., Turgut M., Osborne S., et al.
Haematologica, vol.102, no.11, pp.1913-1922, 2017 (SCI-Expanded)
- LXI. Subsequent malignancies after allogeneic hematopoietic stem cell transplantation**
Gündüz M., Özen M., Şahin U., Toprak S. K., Civriz Bozdağ S., Kurt Yüksel M., Arslan Ö., Özcan M., Demirer T., Bekaç M., et al.
Clinical Transplantation, vol.31, no.7, 2017 (SCI-Expanded)
- LXII. Kronik Myeloid Lösemide Allojenik Nakil ve Tirozin Kinaz İnhibitörlerinin Sağkalıma Etkisi Bir Öncesi-Sonrası Çalışması**
ÖZEN M., ÜSTÜN C., ÖZTÜRK B., TOPÇUOĞLU P., ARAT M., GÜNDÜZ M., ATILLA E., BOLAT G., ARSLAN Ö., DEMİRER T., et al.
Turkish Journal of Hematology, vol.34, no.1, pp.16-26, 2017 (SCI-Expanded)
- LXIII. Kronik Miyeloproliferatif Neoplazi Tanılı Türk Hastaların Geriye Dönük ve Çok Merkezli Analizi**
SOYER N., HAZNEDAROĞLU İ. C., CÖMERT M., ÇEKDEMİR D., YILMAZ M., ÜNAL A., ÇAĞLIYAN G. A., BİLGİR O., İLHAN O., ÖZDEMİRKIRAN F., et al.
Turkish Journal of Hematology, vol.34, no.1, pp.27-33, 2017 (SCI-Expanded)
- LXIV. The effect of age on peripheral stem cell mobilization in healthy donors, single center experience**
Ozen M., Gunduz M., TOPÇUOĞLU P., TOPRAK S. K., DALVA K., Gurman G., İLHAN .
Journal of Clinical Apheresis, vol.32, no.1, pp.16-20, 2017 (SCI-Expanded)
- LXV. Multicenter retrospective analysis of turkish patients with chronic myeloproliferative neoplasms Kronik miyeloproliferatif neoplazi tanılı türk hastaların geriye dönük ve çok merkezli analizi**
Soyer N., HAZNEDAROĞLU İ. C., Cömert M., Çekdemir D., Yılmaz M., ÜNAL A., Çağlıyan G., Bilgir O., İLHAN ., Özdemirkiran F., et al.
Turkish Journal of Hematology, vol.34, no.1, pp.27-33, 2017 (SCI-Expanded)
- LXVI. Allogeneic transplantation in chronic myeloid leukemia and the effect of tyrosine kinase inhibitors**

on survival: A quasi-experimental study Kronik myeloit lösemide allojenik nakil ve tirozin kinaz inhibitörlerinin sağkalıma etkisi bir öncesi-sonrası çalışması

Özen M., Üstün C., Öztürk B., Topçuoğlu P., Arat M., Gündüz M., Atilla E., Bolat G., Arslan Ö., Demirer T., et al.
Turkish Journal of Hematology, vol.34, no.1, pp.16-26, 2017 (SCI-Expanded)

- LXVII. **Constitutional Trisomy 8 Mosaicism with Persistent Macrocytosis**
Altner Ş., KUTLAY N., İLHAN .
Cytogenetic and Genome Research, vol.150, no.1, pp.35-39, 2017 (SCI-Expanded)
- LXVIII. **B-Hücreli Lenfoproliferatif Hastalıkların Dönüm Noktası İdelalisib**
AKSU S., AYYILDIZ O., ETGÜL S., GÖKER H., GÜNEŞ G., HAZNEDAROĞLU İ. C., İLHAN O., KAYNAR L. G., MALKAN U. Y., ÖZDEMİR E., et al.
Uluslararası Hematoloji-Onkoloji Dergisi, vol.26, no.Suppl 1, pp.12-19, 2016 (SCI-Expanded)
- LXIX. **Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study**
O'Brien S., Jones J. A., Coutre S. E., Mato A. R., Hillmen P., Tam C., Österborg A., Siddiqi T., Thirman M. J., Furman R. R., et al.
The Lancet Oncology, vol.17, no.10, pp.1409-1418, 2016 (SCI-Expanded)
- LXX. **Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase**
Saydam G., Haznedaroglu I. C., Kaynar L., Yavuz A. S., Ali R., Guvenc B., Akay O. M., Baslar Z., Ozbek U., Sonmez M., et al.
Expert Opinion on Pharmacotherapy, vol.17, no.14, pp.1851-1858, 2016 (SCI-Expanded)
- LXXI. **İnşaat Esnasında Hematoloji Hastalarında Gelişen Enfeksiyonların Önlenmesinde Portabl Yüksek Etkinlikte Partikül Emici Filtrelerin Etkinliğinin Değerlendirildiği Bir Öncesi Sonrası Çalışması**
ÖZEN M., YILMAZ G., COŞKUN B., TOPÇUOĞLU P., ÖZTÜRK B., GÜNDÜZ M., ATILLA E., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.
Turkish Journal of Hematology, vol.33, no.1, pp.41-47, 2016 (SCI-Expanded)
- LXXII. **Hematopoietic cell transplantation activity of Turkey in 2014: Ongoing increase in HCT rates**
Tekgündüz E., Şencan I., Kapuağasi A., Ünal D., Öztürk M., Gümüş E., Göker H., Tavil E. B., Ertem M., Çetin M., et al.
Transfusion and Apheresis Science, vol.54, no.1, pp.53-59, 2016 (SCI-Expanded)
- LXXIII. **A quasi-experimental study analyzing the effectiveness of portable high-efficiency particulate absorption filters in preventing infections in hematology patients during construction İnşaat esnasında hematoloji hastalarında gelişen enfeksiyonların önlenmesinde portabl yüksek etkinlikte partikül emici filtrelerin etkinliğinin değerlendirildiği bir öncesi sonrası Çalışması**
Özen M., Yılmaz G., Coşkun B., Topçuoğlu P., Öztürk B., Gündüz M., Atilla E., Arslan Ö., Özcan M., Demirer T., et al.
Turkish Journal of Hematology, vol.33, no.1, pp.41-47, 2016 (SCI-Expanded)
- LXXIV. **İdelalisib at the crossroads of B-cell lymphoproliferative disorders B-Hücreli lenfoproliferatif hastalıkların dönüm noktası İdelalisib**
AKSU S., Ayyıldız O., Etgül S., GÖKER H., Gunes G., HAZNEDAROĞLU İ. C., İLHAN ., KAYNAR L., MALKAN Ü. Y., Ozdemir E., et al.
UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, vol.26, pp.12-19, 2016 (SCI-Expanded)
- LXXV. **Stereoide Dirençli Akut Graft Versus Host Hastalığının Tedavisinde Antilenfosit / Timosit Globulin: Bir Merkezdeki 20 Yıllık Deneyim**
ÖZEN M., BOZDAG S. C., ÇAKMAK G., TOPÇUOĞLU P., EROĞLU A. H., GÜNDÜZ M., ARSLAN Ö., DEMİRER T., AKAN H., İLHAN O., et al.
Uluslararası Hematoloji-Onkoloji Dergisi, vol.25, no.4, pp.236-244, 2015 (SCI-Expanded)
- LXXVI. **Human Umbilical Cord Mesenchymal Stromal Cell Transplantation in Myocardial Ischemia (HUC-HEART Trial). A Study Protocol of a Phase 1/2, Controlled and Randomized Trial in Combination with Coronary Artery Bypass Grafting**
CAN A., Ulus A. T., ÇINAR Ö., TOPAL ÇELİKKAN F., Simsek E., AKYOL M., CANPOLAT U., Erturk M., Kara F., İLHAN .
Stem Cell Reviews and Reports, vol.11, no.5, pp.752-760, 2015 (SCI-Expanded)
- LXXVII. **Peripheral blood stem cell mobilization and collection from elderly patients and elderly healthy**

donor

Bozdog S. C., İLHAN .

Transfusion and Apheresis Science, vol.53, no.1, pp.8-12, 2015 (SCI-Expanded)

- LXXVIII. **Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: Results of the randomized NHL13 trial**
Jaeger U., Trneny M., Melzer H., Praxmarer M., Nawarawong W., Yehuda D. B., Goldstein D., Mihaljevic B., İLHAN ., Ballova V., et al.
Haematologica, vol.100, no.7, pp.955-963, 2015 (SCI-Expanded)
- LXXIX. **Clinical characteristics and therapeutic outcomes of elderly patients with chronic myeloid leukemia: A retrospective multicenter study**
Korkmaz S., Dal M. S., Berber I., Sahin D. G., Dogu M. H., Ayyildiz O., Nizam I., Albayrak M., Esen R., Namdaroglu S., et al.
Geriatrics and Gerontology International, vol.15, no.6, pp.729-735, 2015 (SCI-Expanded)
- LXXX. **Hyperviscosity in renal transplant recipients**
Tutal E., Erkmen Uyar M., Uyanik S., Bal Z., Guliyev O., TOPRAK S. K., İLHAN ., Sezer S., Haberal M.
Transplantation Proceedings, vol.47, no.4, pp.1165-1169, 2015 (SCI-Expanded)
- LXXXI. **Antilymphocyte/thymocyte globulin for the treatment of steroid-refractory acute graft-versus-host disease: 20-year experience at a single center Steroide dirençli akut graft versus host hastalığının tedavisinde antilenfosit / Timosit globulin: Bir merkezdeki 20 yıllık deneyim**
Ozen M., Bozdog S. C., Cakmak G., TOPÇUOĞLU P., EROĞLU A. H., Gunduz M., ARSLAN Ö., DEMİRER T., Akan H., İLHAN ., et al.
UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, vol.25, no.4, pp.236-244, 2015 (SCI-Expanded)
- LXXXII. **Clinical characteristics, post-treatment assessment and prognostic factors affecting patient survival of patients at 65 years of age or older with hodgkin lymphoma: A retrospective multicenter study from Turkey**
Berber I., Erkurt M. A., Keklik M., Dogu M. H., Terzi H., Pala C., Sari H. I., Sencan M., Sivgin S., Hacıoglu S., et al.
Acta Medica Mediterranea, vol.31, no.6, pp.1195-1202, 2015 (SCI-Expanded)
- LXXXIII. **Therapeutic plasmapheresis in geriatric patients: Favorable results**
Ataca P., Marasuna O. A., Ayyildiz E., BAY M., İLHAN .
Transfusion and Apheresis Science, vol.51, no.3, pp.64-67, 2014 (SCI-Expanded)
- LXXXIV. **Quilty Effect after Extracorporeal Photopheresis in a Patient with Severe Refractory Cardiac Allograft Rejection**
ÖZCAN Ö. U., SAYIN T., SÖĞÜT G., HEPER A., GÖKSÜLÜK H., VURGUN V. K., KAYA C. T., ÜSTÜN E. E., İLHAN O., EROL Ç.
Turkish Journal of Hematology, vol.31, no.4, pp.90-91, 2014 (SCI-Expanded)
- LXXXV. -
AYYILDIZ O., DEMİRKAN F., GÖKER H., HAZNEDAROĞLU İ. C., İLHAN O., KAYNAR L. G., ÖZDEMİR E., SAYDAM G., SAYINALP N., ŞAHİN F., et al.
Uluslararası Hematoloji-Onkoloji Dergisi, vol.253, pp.4-14, 2014 (SCI-Expanded)
- LXXXVI. **Ibrutinib: From Molecule to Medicine İbrutinib: Molekülden İlaç**
Ayyildiz O., Demirkan F., GÖKER H., HAZNEDAROĞLU İ. C., İLHAN ., KAYNAR L., Ozdemir E., Saydam G., SAYINALP N., Sahin F., et al.
UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, vol.24, no.3, pp.4-14, 2014 (SCI-Expanded)
- LXXXVII. **Quilty effect after extracorporeal photopheresis in a patient with severe refractory cardiac allograft rejection Şiddetli Kardiyak Allogreft Rejeksiyonu Olan Bir Hastada Ekstrakorporeal Fotoferez Sonrası Quilty Etkisi**
Özcan Ö. U., SAYIN T., Soğut G., HEPER A., Gökşülük H., Vurgun V. K., TULUNAY KAYA C., Üstün E. E., İLHAN ., EROL Ç.
Turkish Journal of Hematology, vol.31, no.4, pp.430-431, 2014 (SCI-Expanded)
- LXXXVIII. **The treatment of acquired hemophilia with combination therapy of immunosuppressives and immunoabsorption Kazanı{dotless}lmi{dotless}ş hemofilinin immunsupresif ve immunoabsorbsiyon kombinasyonu ile tedavisi**
Bilgin A. U., ÖZCAN M., Ayyildiz E., İLHAN .

- Turkish Journal of Hematology, vol.31, no.2, pp.194-196, 2014 (SCI-Expanded)
- LXXXIX. **RHuEPO hyporesponsiveness and related high dosages are associated with hyperviscosity in maintenance hemodialysis patients**
Erkmen Uyar M., TOPRAK S. K., Saglam H., Tural E., BAY M., İLHAN ., Bal Z., Sezer S.
The Scientific World Journal, vol.2013, 2013 (SCI-Expanded)
- XC. **Therapeutic plasma exchange in patients with neurological diseases: Multicenter retrospective analysis**
Kaya E., Keklik M., Şencan M., Yilmaz M., Keskin A., Kiki I., Erkurt M. A., Şivgin S., Korkmaz S., Okan V., et al.
Transfusion and Apheresis Science, vol.48, no.3, pp.349-352, 2013 (SCI-Expanded)
- XCI. **Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura: A retrospective multicenter study**
Korkmaz S., Keklik M., Sivgin S., Yildirim R., Tombak A., Kaya M. E., Acik D. Y., Esen R., Hacıoglu S. K., Sencan M., et al.
Transfusion and Apheresis Science, vol.48, no.3, pp.353-358, 2013 (SCI-Expanded)
- XCII. **Double filtration plasmapheresis for a case of Crimean-Congo hemorrhagic fever**
MEÇO B. C., MEMİKOĞLU K. O., İLHAN ., Ayyildiz E., Gunt C., ÜNAL M. N., Oral M., Tulunay M.
Transfusion and Apheresis Science, vol.48, no.3, pp.331-334, 2013 (SCI-Expanded)
- XCIII. **Review of therapeutic options and the management of patients with myelodysplastic syndromes**
Özcan M. A., İLHAN ., Ozcebe O. I., Nalcaci M., Gülbas Z.
Expert Review of Hematology, vol.6, no.2, pp.165-189, 2013 (SCI-Expanded)
- XCIV. **Türk kronik myeloid lösemi çalışması: KML hastalarının geriye dönük kesitsel incelenmesi**
ŞAHİN F., SAYDAM G., CÖMERT M., UZ B., YAVUZ A. S., TURAN E., HİNDİLERDEN İ. Y., ATAY M. H., KELTİKLİ E., TURGUT M., et al.
Turkish Journal of Hematology, vol.30, no.4, pp.351-358, 2013 (SCI-Expanded)
- XCv. **Adsorptive leukocytapheresis in inflammatory bowel diseases: Our preliminary results are encouraging**
TÖRÜNER M., TOPRAK S. K., MIZRAK K., YILDIRIM Y., BAY M., AYYILDIZ E., İLHAN O.
Turkish Journal of Hematology, vol.30, no.2, pp.219-220, 2013 (SCI-Expanded)
- XCVI. **Adsorptive leukocytapheresis in inflammatory bowel diseases: Our preliminary results are encouraging İnfl amatuvar Barsak Hastalıklarında Adzorzitif Lökositaferez Uygulamas?: İlk Sonuçlarımız Oldukça Cesaret Verici**
TÖRÜNER M., TOPRAK S. K., Mizrak K., Yildirim Y., BAY M., Ayyildiz E., İLHAN .
Turkish Journal of Hematology, vol.30, no.2, pp.219-220, 2013 (SCI-Expanded)
- XCvII. **Turkish Apheresis Activity for 2011**
ALTUNTAŞ F., Unal A., İLHAN .
Transfusion and Apheresis Science, vol.47, no.1, pp.57-58, 2012 (SCI-Expanded)
- XCvIII. **Older age and capacity of colony forming unit in autologous peripheral derived hematopoietic cells**
Civriz Bozdag S., BAY M., Ayyildiz E., TOPÇUOĞLU P., İLHAN .
Transfusion and Apheresis Science, vol.47, no.1, pp.113-116, 2012 (SCI-Expanded)
- XCIX. **Plerixafor use in patients with previous mobilization failure: A multicenter experience**
Tekgündüz E., Altuntaş F., Şivgin S., Aki Ş. Z., Dönmez A., Topçuoğlu P., Yildirim R., Baysal N. A., Ayyildiz E., Yüksel M. K., et al.
Transfusion and Apheresis Science, vol.47, no.1, pp.77-80, 2012 (SCI-Expanded)
- C. **Impact of age and diagnosis on viability during centrifugation and cryopreservation of peripheral blood stem cell products**
Civriz Bozdag S., BAY M., Ayyildiz E., TOPÇUOĞLU P., İLHAN .
Transfusion and Apheresis Science, vol.47, no.1, pp.117-120, 2012 (SCI-Expanded)
- CI. **Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients**
TOPÇUOĞLU P., Arat M., ÖZCAN M., ARSLAN Ö., İLHAN ., Beksac M., Gurman G.
Annals of Hematology, vol.91, no.4, pp.577-586, 2012 (SCI-Expanded)
- CII. **Therapeutic plasma exchange in an intensive care unit (ICU): A 10-year, single-center experience**

OZANSOY A., CAN Ö., Oral M., ÜNAL M. N., Ayyildiz E., İLHAN ., Tulunay M.

Transfusion and Apheresis Science, vol.45, no.2, pp.161-166, 2011 (SCI-Expanded)

- CIII. **The management of Chronic Myeloid Leukemia in the era of second generation tyrosine kinase Inhibitors**
HAZNEDAROĞLU İ. C., Cetiner M., İLHAN .
UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, vol.21, no.2 SUPPL. 1, pp.1-3, 2011 (SCI-Expanded)
- CIV. **Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: Results of a randomized multicenter phase III trial**
Beksac M., Ali R., Ozcelik T., ÖZCAN M., Ozcebe O., BAYIK M. M., PAYDAŞ S., BÜYÜKAŞIK Y., İLHAN ., ÖZKALEMKAŞ F., et al.
Leukemia Research, vol.35, no.3, pp.340-345, 2011 (SCI-Expanded)
- CV. **Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors**
Gupta V., Eapen M., Brazauskas R., Carreras J., Aljurf M., Gale R. P., Hale G. A., İLHAN ., Passweg J. R., Ringdén O., et al.
Haematologica, vol.95, no.12, pp.2119-2125, 2010 (SCI-Expanded)
- CVI. **The effect of CD34 count and clonogenic potential of hematopoietic stem cells on engraftment**
Sari T., YÜKSEL M., TOPÇUOĞLU P., BAY M., Ayyildiz E., ÖZCAN M., İLHAN .
Transfusion and Apheresis Science, vol.43, no.3, pp.315-320, 2010 (SCI-Expanded)
- CVII. **Remission of severe autoimmune bullous disorders induced by long-term extracorporeal photochemotherapy**
ŞANLI H., AKAY B. N., Ayyildiz E., Anadolu R., İLHAN .
Transfusion and Apheresis Science, vol.43, no.3, pp.353-359, 2010 (SCI-Expanded)
- CVIII. **Chronic myeloid leukemia: Practical issues in diagnosis, treatment and follow-up**
Buyukasik Y., Haznedaroglu I. C., İLHAN .
UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, vol.20, no.2 SUPPL., pp.1-12, 2010 (SCI-Expanded)
- CIX. **Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation**
Shaughnessy P., Bolwell B., Van Besien K., Mistrik M., Grigg A., Dodds A., Prince H., Durrant S., İLHAN ., Parenti D., et al.
Bone Marrow Transplantation, vol.45, no.6, pp.1068-1076, 2010 (SCI-Expanded)
- CX. **Propofol/dexmedetomidine and propofol/ketamine combinations for anesthesia in pediatric patients undergoing transcatheter atrial septal defect closure: A prospective randomized study**
Koruk S., Mizrak A., Kaya Ugur B., İLHAN ., Baspinar O., Oner U.
Clinical Therapeutics, vol.32, no.4, pp.701-709, 2010 (SCI-Expanded)
- CXI. **The clonogenic potential of hematopoietic stem cells and mesenchymal stromal cells in various hematologic diseases: A pilot study**
YÜKSEL M., TOPÇUOĞLU P., Kurdal M., İLHAN .
Cytotherapy, vol.12, no.1, pp.38-44, 2010 (SCI-Expanded)
- CXII. **Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: A randomized evaluation of early vs late administration of recombinant human G-CSF**
Ozcelik T., TOPÇUOĞLU P., Beksac M., ÖZCAN M. E., Arat M., Bykl Z., Bakanay S., İLHAN ., Gurman G., ARSLAN Ö., et al.
Bone Marrow Transplantation, vol.44, no.12, pp.779-783, 2009 (SCI-Expanded)
- CXIII. **Effects of imatinib mesylate on Renin-Angiotensin System (RAS) activity during the clinical course of chronic myeloid leukaemia**
Sayitoglu M., Haznedaroglu I. C., Hatirnaz O., Erbilgin Y., Aksu S., Koca E., Adiguzel C., Bayik M., Akalin I., Gülbas Z., et al.
Journal of International Medical Research, vol.37, no.4, pp.1018-1028, 2009 (SCI-Expanded)
- CXIV. **Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma**
Fenske T. S., Hari P. N., Carreras J., Zhang M., Kamble R. T., Bolwell B. J., Cairo M. S., Champlin R. E., Chen Y., Freytes C. O., et al.

Biology of Blood and Marrow Transplantation, vol.15, no.11, pp.1455-1464, 2009 (SCI-Expanded)

- CXV. **Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia**
Lee S. J., Kukreja M., Wang T., Giralto S. A., Szer J., Arora M., Woolfrey A. E., Cervantes F., Champlin R. E., Gale R. P., et al.
Blood, vol.112, no.8, pp.3500-3507, 2008 (SCI-Expanded)
- CXVI. **A case report of the Modified Malmö Protocol: An alternative therapeutic approach to refractory chronic idiopathic thrombocytopenic purpura**
Yazman D., Konuk N., ÖZCAN M., Arat M., SOYDAN E., ARSLAN Ö., İLHAN .
Therapeutic Apheresis and Dialysis, vol.12, no.3, pp.255-258, 2008 (SCI-Expanded)
- CXVII. **Vitiligo after hematopoietic cell transplantation: Six cases and review of the literature**
ŞANLI H., AKAY B. N., Arat M., KOÇYİĞİT P., Akan H., Beksac M., İLHAN .
Dermatology, vol.216, no.4, pp.349-354, 2008 (SCI-Expanded)
- CXVIII. **HLA-Identical Sibling Allogeneic Transplants versus Chemotherapy in Acute Myelogenous Leukemia with t(8;21) in First Complete Remission: Collaborative Study between the German AML Intergroup and CIBMTR**
Schlenk R. F., Pasquini M. C., Pérez W. S., Zhang M., Krauter J., Antin J. H., Bashey A., Bolwell B. J., Büchner T., Cahn J., et al.
Biology of Blood and Marrow Transplantation, vol.14, no.2, pp.187-196, 2008 (SCI-Expanded)
- CXIX. **Comparison of different needle diameters and flow rates on bone marrow mononuclear stem cell viability: An ex vivo experimental study**
BAY M., AKAR A. R., Durdu S., Ayyildiz E., İLHAN .
Cytotherapy, vol.10, no.1, pp.98-99, 2008 (SCI-Expanded)
- CXX. **How to calculate the quantity of CD34+ cells infused? A single center cohort study based on actual, ideal or adjusted ideal body weight**
TOPÇUOĞLU P., SOYDAN E., Ekiz F., Ayyildiz E., DALVA K., ÖZCAN M., ARSLAN Ö., Arat M., İLHAN .
Transfusion and Apheresis Science, vol.36, no.3, pp.275-280, 2007 (SCI-Expanded)
- CXXI. **Novel chromosomal translocations in multiple myeloma: t(13;16)(q14;q24) and t(1;15)(q10;q26)**
Akalin I., KUTLAY N., İLHAN ., Tukun A.
International Journal of Laboratory Hematology, vol.29, no.3, pp.215-220, 2007 (SCI-Expanded)
- CXXII. **Impact of harvest product volume in erythrocyte depletion of allogeneic or autologous bone marrow using COBE spectra**
SOYDAN E., Ayyildiz E., DALVA K., TOPÇUOĞLU P., BAY M., ARSLAN Ö., İLHAN ., Arat M.
Transfusion and Apheresis Science, vol.36, no.3, pp.269-273, 2007 (SCI-Expanded)
- CXXIII. **The effect of extracorporeal photoimmunotherapy (ECP) on serum TNF- α level in chronic graft versus host disease (GvHD)**
Ayyildiz E., ARSLAN Ö., TOPÇUOĞLU P., Arat M., DALVA K., SOYDAN E., BAY M., İLHAN .
Transfusion and Apheresis Science, vol.36, no.1, pp.79-85, 2007 (SCI-Expanded)
- CXXIV. **Therapeutic plasma exchange in the treatment of neuroimmunologic disorders: Review of 50 cases**
YÜCESAN C., Arslan Ö., Arat M., Yüçemen N., Ayyildiz E., İLHAN ., Mutluer N.
Transfusion and Apheresis Science, vol.36, no.1, pp.103-107, 2007 (SCI-Expanded)
- CXXV. **Effects of plasma nitric oxide levels on platelet activation in single donor apheresis and random donor concentrates**
Büyükkagıncı D. I., İLHAN ., Kavas G. Ö., ARSLAN Ö., Arat M., DALVA K., Ayyildiz E.
Transfusion and Apheresis Science, vol.36, no.1, pp.73-78, 2007 (SCI-Expanded)
- CXXVI. **Does continuous flow apheresis influence viability in allogeneic hematopoietic stem cell harvest?**
Bakanay S. M., DALVA K., Arat M., ARSLAN Ö., Ayyildiz E., Beksac M., İLHAN .
Transfusion and Apheresis Science, vol.34, no.2, pp.171-178, 2006 (SCI-Expanded)
- CXXVII. **Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission**
Tallman M. S., Pérez W. S., Lazarus H. M., Gale R. P., Maziarz R. T., Rowe J. M., Marks D. I., Cahn J., Bashey A., Bishop

- M. R., et al.
Biology of Blood and Marrow Transplantation, vol.12, no.2, pp.204-216, 2006 (SCI-Expanded)
- CXXVIII. **Expression of IFITM1 in chronic myeloid leukemia patients**
Akcyerli C. B., Beksac M., Holko M., Frevel M., DALVA K., Özbek U., SOYDAN E., ÖZCAN M., Özet G., İLHAN ., et al.
Leukemia Research, vol.29, no.3, pp.283-286, 2005 (SCI-Expanded)
- CXXIX. **High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma - A retrospective evaluation**
DEMİRER T., Ayli M., Fen T., ÖZCAN M. E., Arat M., Büyükberber S., ARSLAN Ö., Gurman G., Akan H., İLHAN .
Bone Marrow Transplantation, vol.34, no.9, pp.781-786, 2004 (SCI-Expanded)
- CXXX. **Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease**
İLHAN ., Arat M., ARSLAN Ö., Ayyildiz E., Sanli H., Beksac M., ÖZCAN M., Gürman G., Akan H.
Transfusion and Apheresis Science, vol.30, no.3, pp.185-187, 2004 (SCI-Expanded)
- CXXXI. **Transfusion and Apheresis Science: Introduction**
İLHAN .
Transfusion and Apheresis Science, vol.30, no.3, pp.179-180, 2004 (SCI-Expanded)
- CXXXII. **Therapeutic plasma exchange in a single center: Ibni Sina experience**
ARSLAN Ö., Arat M., Tek I., Ayyildiz E., İLHAN .
Transfusion and Apheresis Science, vol.30, no.3, pp.181-184, 2004 (SCI-Expanded)
- CXXXIII. **Peripheral blood stem cell apheresis for allogeneic transplants: Ibni Sina experience**
Arat M., ARSLAN Ö., Ayyildiz E., TOPÇUOĞLU P., DALVA K., İLHAN .
Transfusion and Apheresis Science, vol.30, no.3, pp.189-191, 2004 (SCI-Expanded)
- CXXXIV. **Simultaneous Onset of Chronic Graft Versus Host Disease and Alopecia Areata Following Allogeneic Haematopoietic Cell Transplantation [11]**
ŞANLI H., Kusak F., Arat M., Ekmekci P., İLHAN .
Acta Dermato-Venereologica, vol.84, no.1, pp.86-87, 2004 (SCI-Expanded)
- CXXXV. **Effects of replacement fluids used for therapeutic plasma exchange on plasma viscosity and plasma oncotic pressure**
Tek I., ARSLAN Ö., Arat M., Ayyildiz E., BAY M., Oral M., İLHAN .
Transfusion and Apheresis Science, vol.31, no.2, pp.89-93, 2004 (SCI-Expanded)
- CXXXVI. **The impact of granulocyte colony stimulating factor at content of donor lymphocytes collected for cellular immunotherapy**
Arat M., ARSLAN Ö., Gürman G., DALVA K., ÖZCAN M., Uğur A., İLHAN .
Transfusion and Apheresis Science, vol.30, no.1, pp.9-15, 2004 (SCI-Expanded)
- CXXXVII. **Role of pretransplant interferon- α (IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogenous leukemia (CML): Results from three Turkish transplant centers**
Beksac M., Çelebi H., Sargın D., Yalcin A., Topcuoglu P., Kalayoglu-Besisik S., Beyan C., Arslan O., Ozcan M., Gurman G., et al.
Bone Marrow Transplantation, vol.31, no.10, pp.897-904, 2003 (SCI-Expanded)
- CXXXVIII. **High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: A retrospective evaluation**
DEMİRER T., Uysal V., Ayli M., Genc Y., İLHAN ., Koc H., Dagli M., Arat M., Gunel N., Fen T., et al.
Bone Marrow Transplantation, vol.31, no.9, pp.755-761, 2003 (SCI-Expanded)
- CXXXIX. **The detection of flow cytometric G-CSF receptor expression and it's effect on therapy in acute myeloid leukemia**
KUTLAY S., Beksac M., DALVA K., İLHAN ., Koc H., Akan H., ÖZCAN M.
Leukemia and Lymphoma, vol.44, no.5, pp.791-795, 2003 (SCI-Expanded)
- CXL. **Effects of replacement fluids on coagulation system used for therapeutic plasma exchange**
Tek I., ARSLAN Ö., Arat M., ÖZCAN M., Akdağ B., İLHAN .
Transfusion and Apheresis Science, vol.28, no.1, pp.3-7, 2003 (SCI-Expanded)

- CXLI. **Malpositioning of Hickman catheters, left versus right sided attempts**
ÜNAL A. E., BAYAR S., Arat M., İLHAN .
Transfusion and Apheresis Science, vol.28, no.1, pp.9-12, 2003 (SCI-Expanded)
- CXLII. **Severity of chronic graft-versus-host disease: Association with treatment-related mortality and relapse**
Lee S. J., Klein J. P., Barrett A. J., Ringden O., Antin J. H., Cahn J., Carabasi M. H., Gale R. P., Giralto S., Hale G. A., et al.
Blood, vol.100, no.2, pp.406-414, 2002 (SCI-Expanded)
- CXLIII. **An unusual presentation of plasma cell dyscrasias: Cardiac tamponade due to myelomatous infiltration**
Arat M., Ulusoy V., DEMİRER T., Uysal A. V., ÖZCAN M., Dinçer S., İLHAN ., Koç H.
Leukemia and Lymphoma, vol.43, no.1, pp.145-148, 2002 (SCI-Expanded)
- CXLIV. **A randomized trial of assessment of efficacy of leukapheresis volumes, 8 liters vs 12 liters**
DEMİRER T., Dagli M., İLHAN ., Ayli M., Haznedar R., Fen T., Gunel N., YAVUZ Y., Arat M., ÖZCAN M. E., et al.
Bone Marrow Transplantation, vol.29, no.11, pp.893-897, 2002 (SCI-Expanded)
- CXLV. **In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia**
Üstün C., Beksac M., DALVA K., Koc H., Konuk N., İLHAN ., ÖZCAN M. E., TOPÇUOĞLU P., KARASOY D., HAYRAN K. M.
Medical Oncology, vol.19, no.1, pp.59-67, 2002 (SCI-Expanded)
- CXLVI. **Effects of DMSO on platelet functions and P-Selectin expression during storage**
Cetin M., Eser B., Er Ö., ÜNAL A., KILIÇ E., Patiroglu T., Senol Coskun H., Altinbas M., ARSLAN Ö., İLHAN .
Transfusion and Apheresis Science, vol.24, no.3, pp.261-267, 2001 (SCI-Expanded)
- CXLVII. **The effect of G-CSF on lymphocyte subsets and CD34+ cells in allogeneic stem cell transplantation**
Gürman G., Dilek I., ARSLAN Ö., Arat M., Beksac M., İLHAN ., ÖZCAN M., Akan H., DALVA K., Konuk N., et al.
Transfusion and Apheresis Science, vol.24, no.1, pp.23-28, 2001 (SCI-Expanded)
- CXLVIII. **Extramedullary relapse following allogeneic stem cell transplantation in acute promyelocytic leukemia: the role of ATRA.**
Ustün C., Arat M., Celebi H., Akan H., İLHAN ., Ozçelik T., Burgess R., Koc H.
Haematologica, vol.86, no.10, 2001 (SCI-Expanded)
- CXLIX. **CD41+ and CD42+ hematopoietic progenitor cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation**
DEMİRER T., İLHAN ., Arat M., YAVUZ Y., ÖZCAN M. E., DALVA K., ÇELEBİ H., Beksac M., Akan H., Gürman G., et al.
Journal of Clinical Apheresis, vol.16, no.2, pp.67-73, 2001 (SCI-Expanded)
- CL. **Treatment of extensive chronic sclerodermatous graft-versus-host disease with high-dose immunosuppressive therapy and CD34+ autologous stem cell rescue [4]**
Arat M., İLHAN ., İyan E. A., Çelebi H., Koç H., Akan H.
Blood, vol.98, no.3, pp.892-893, 2001 (SCI-Expanded)
- CLI. **Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation**
ÖZCAN M. E., Üstün C., Akçağlayan E., Akan H., ARSLAN Ö., İLHAN ., Beksac M., Gürman G., DEMİRER T., Arat M., et al.
Bone Marrow Transplantation, vol.27, no.5, pp.499-505, 2001 (SCI-Expanded)
- CLII. **Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies**
Gürman G., Arat M., İLHAN ., Konuk N., Beksac M., ÇELEBİ H., ÖZCAN M. E., ARSLAN Ö., Üstün C., Akan H., et al.
Cytotherapy, vol.3, no.4, pp.253-260, 2001 (SCI-Expanded)
- CLIII. **Circulating CD44 and intercellular adhesion molecule-1 levels in low grade non-hodgkin lymphoma and B-cell chronic lymphocytic leukemia patients during interferon- α -2a treatment**
Beksa M., Arat M., Akan H., Ko H., İLHAN ., ÖZCAN M.
Cancer, vol.89, no.7, pp.1474-1481, 2000 (SCI-Expanded)
- CLIV. **Allogeneic peripheral blood stem cell transplantation for standard risk leukemia: Experience of İbni Sina Hospital**
ARSLAN Ö., COŞKUN H., Arat M., ÇELEBİ H., ÖZCAN M. E., Gürman G., Üstün C., DEMİRER T., Akan H., İLHAN ., et al.

Bone Marrow Transplantation, vol.25, no.12, pp.1229-1232, 2000 (SCI-Expanded)

- CLV. **Soluble adhesion molecules (sICAM-1, sL-Selectin, sE-Selectin, sCD44) in healthy allogeneic peripheral stem-cell donors primed with recombinant G-CSF**
ARSLAN Ö., Akan H., Arat M., DALVA K., ÖZCAN M. E., Gurman G., İLHAN ., Konuk N., Beksac M., Uysal A., et al.
Cytotherapy, vol.2, no.4, pp.259-265, 2000 (SCI-Expanded)
- CLVI. **A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies**
DEMİRER T., İLHAN ., Mandel N., Arat M., Günel N., ÇELEBİ H., Üstün C., Akan H., Demirer S., Aydintuğ S., et al.
Bone Marrow Transplantation, vol.25, no.7, pp.697-703, 2000 (SCI-Expanded)
- CLVII. **Treatment results in aplastic anemia trials need to be analyzed separately for pediatric and adult populations [4] (multiple letters)**
Reddy V., Khan S., Wingard J., Mehta P., Marsh J., Schrezenmeier H., Marin P., İLHAN ., McCann S., Socie G., et al.
Blood, vol.94, no.5, pp.1833-1834, 1999 (SCI-Expanded)
- CLVIII. **Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: A report from the European blood and marrow transplant (EBMT) severe aplastic anaemia working party**
Marsh J., Schrezenmeier H., Marin R., İLHAN ., Ljungman P., McCann S., Socie G., Tichelli A., Passweg J., Hows J., et al.
Blood, vol.93, no.7, pp.2191-2195, 1999 (SCI-Expanded)
- CLIX. **The impact of the CD34+ cell dose on engraftment in allogeneic peripheral blood stem cell transplantation**
İLHAN ., ARSLAN Ö., Arat M., Beksac M., Akan H., Özcan M., Gürman G., Konuk N., Uysal A., Koç H.
Transfusion Science, vol.20, no.1, pp.69-71, 1999 (SCI-Expanded)
- CLX. **Hematopoietic stem cell transplantation from non-replicative hepatitis B virus carriers is safe**
Üstün C., İDİLMAN R., Gürman G., ÖZCAN M., AKYOL G., Akan H., İLHAN ., Beksac M., Uysal A., Konuk N., et al.
Journal of Hepatology, vol.31, no.2, pp.202-209, 1999 (SCI-Expanded)
- CLXI. **Autoimmune thrombocytopenia in a patient with small cell lung cancer developing after chemotherapy and resolving following autologous peripheral blood stem cell transplantation**
DEMİRER T., ÇELEBİ H., Arat M., Üstün C., DEMİRER S., Dilek I., ÖZCAN M. E., İLHAN ., Akan H., Gürman G., et al.
Bone Marrow Transplantation, vol.24, no.3, pp.335-337, 1999 (SCI-Expanded)
- CLXII. **Incidence of tuberculosis after bone marrow transplantation in a single center from Turkey**
ARSLAN Ö., Gürman G., Dilek I., ÖZCAN M., Koç H., İLHAN ., Akan H., Konuk N., Uysal A., Beksac M.
Haematologia, vol.29, no.1, pp.59-62, 1998 (SCI-Expanded)
- CLXIII. **Resistant graft failure overcome with allogeneic peripheral blood plus bone marrow stem cells**
ARSLAN Ö., Seferoğlu A., Gürman G., İLHAN ., Koç H.
Haematologia, vol.29, no.1, pp.47-50, 1998 (SCI-Expanded)
- CLXIV. **Allogeneic peripheral blood stem cell transplantation in acute non-lymphoblastic leukemia**
ARSLAN Ö., Üstün C., Arat M., Çelebi H., Akan H., Beksac M., İLHAN ., Gürman G., ÖZCAN M., Konuk N., et al.
Hematological Oncology, vol.16, no.4, pp.155-162, 1998 (SCI-Expanded)
- CLXV. **Serum erythropoietin levels in patients with leukemia on cytostatic treatment**
Aydogdu I., İLHAN ., Beksac M., Koc H., Akan H., Konuk N., Uysal A.
Haematologia, vol.29, no.2, pp.133-137, 1998 (SCI-Expanded)
- CLXVI. **Acquired ichthyosis associated with chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation in a patient with chronic myelogenous leukemia**
Dilek I., DEMİRER T., Üstün C., Arat M., Koç H., Beksac M., Erdi H., ANADOLU R. Y., Özcan M., İLHAN ., et al.
Bone Marrow Transplantation, vol.21, no.11, pp.1159-1161, 1998 (SCI-Expanded)
- CLXVII. **Administration of MINE protocol in untreated patients with intermediate and high grade non-Hodgkin's lymphoma**
Aydogdu I., Koc H., İLHAN ., Gurman G., Akan H., Beksac M., Konuk N., Uysal A., Ozerol E.
Haematologia, vol.28, no.4, pp.207-213, 1997 (SCI-Expanded)

- CLXVIII. **A case report of a patient who has pure red cell aplasia and rheumatoid arthritis**
Üstün C., Karavelioğlu D., İLHAN ., Aydıntuğ O., Beksaç M.
International Journal of Hematology, vol.66, no.4, pp.505-512, 1997 (SCI-Expanded)
- CLXIX. **Hepatitis B virus infection in allogeneic bone marrow transplantation**
Üstün C., Koç H., Karayalçın S., AKYOL G., Gürman G., İLHAN ., Akan H., ÖZCAN M. E., ARSLAN Ö., Konuk N., et al.
Bone Marrow Transplantation, vol.20, no.4, pp.289-296, 1997 (SCI-Expanded)
- CLXX. **Febrile neutropenia in a bone marrow transplantation unit**
Akan H., Koç H., ARSLAN Ö., Beksaç M., İLHAN ., Gürman G., ÖZCAN M., Üstün C., Konuk N., Uysal A.
International Journal of Antimicrobial Agents, vol.8, no.2, pp.127-130, 1997 (SCI-Expanded)
- CLXXI. **Allogeneic peripheral blood stem cell transplantation: Is there an increased risk of graft vs host disease in leukemia patients?**
Koç H., Gürman G., ARSLAN Ö., ÖZCAN M. E., Dilek I., Akan H., İLHAN ., Konuk N., Beksaç M., Uysal A.
Journal of Chemotherapy, vol.9, no.5, pp.371-376, 1997 (SCI-Expanded)
- CLXXII. **Hemorrhagic cystitis as a complication of bone marrow transplantation**
İLHAN ., Koç H., Akan H., Gürman G., ARSLAN Ö., ÖZCAN M. E., Arikan N., Sencer H., Konuk N., Uysal A., et al.
Journal of Chemotherapy, vol.9, no.1, pp.56-61, 1997 (SCI-Expanded)
- CLXXIII. **Use of high-dose chemotherapy plus granulocyte colony-stimulating factor for the salvage of refractory or resistant-relapse lymphoma patients without stem cell support**
Koç H., ARSLAN Ö., Gürman G., Akan H., ÖZCAN M., İLHAN ., Aydoğdu İ., Arat M., Beksaç M., Konuk N., et al.
Acta Haematologica, vol.98, no.3, pp.136-139, 1997 (SCI-Expanded)

Books & Book Chapters

I. Editöryal

İLHAN O., TOPRAK S. K.

in: Hematoloji ve COVID-19 - 2020 (Kitap Editörlüğü), İlhan Osman, Toprak Selami Koçak, Editor, Türkiye Klinikleri, Ankara, pp.1-116, 2020

Refereed Congress / Symposium Publications in Proceedings

- I. **the impact of pretransplant immunomodulatory drugs on cmv reactivation**
YÜKSEL M., CENGİZ SEVAL G., USLU A., KIRCALI E., KOYUN D., YAVUZ G., KARAKAYA B., NARLI ÖZDEMİR Z., ÇINAR G., CİVRİZ BOZDAĞ S., et al.
8th International Congress on Leukemia Lymphoma Myeloma, 10 January 2021
- II. **PATIENT RELATED FACTORS OVERRIDE LENALIDOMIDE MAINTENANCE AS A FACTOR OF SEVERITY FOR COVID-19 INFECTION**
KIRCALI E., CENGİZ SEVAL G., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., İLHAN O., BEKSAÇ M.
8th International Congress on Leukemia Lymphoma Myeloma, 21 May 2021
- III. **TİROZİN KİNAZ İNHİBİTÖRLERİNİ KESME KARARINDA KEMİKİLİĞİNDEKİ LÖSEMİK KÖK HÜCRE VARLIĞININ ÖNEMİ**
İLHAN O., NARLI ÖZDEMİR Z., ARSLAN A., OKAY M., İPEK Ş., DALVA K., SAYDAM G., HAZNEDAROĞLU İ. C.
46. Ulusal Hematoloji Kongresi, Turkey, 28 - 31 October 2020
- IV. **DECISION TO STOP TYROSINE KINASE INHIBITORS (TKIS) WITH BONE MARROW LEUKEMIC STEM CELL LEVEL: DETECTION OF BCR-ABL IN PERIPHERAL BLOOD MAY NOT BE ENOUGH**
İLHAN O., NARLI ÖZDEMİR Z., ARSLAN A., OKAY M., İPEK Ş., DALVA K., SAYDAM G., HAZNEDAROĞLU İ. C.
25th European Hematology Congress Virtual, 11 - 21 June 2020
- V. **Allogeneic hematopoietic stem cell transplantation for primary myelofibrosis: A single-center experience**
DEMİRER T., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., İLHAN O., GÜRMAN G.,

BEKSAÇ M., ÖZCAN M.

2020 American Society of Clinical Oncology (ASCO) Annual Meeting, 29 May - 02 June 2020, vol.38, pp.19522

- VI. **A real-world single-center retrospective study on efficacy and safety of pegylated interferon alpha-2a in patients with myeloproliferative neoplasm**
ÖZCAN M., KOYUN D., CENGİZ SEVAL G., USLU A., KIRCALI E., ÖZTÜRK C., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., et al.
2020 American Society of Clinical Oncology (ASCO) Annual Meeting, 29 May - 02 June 2020
- VII. **Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis**
CENGİZ SEVAL G., Öztürk N., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., et al.
Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR, Orlando, United States Of America, 19 - 23 February 2020, vol.26, pp.109-110
- VIII. **Ibrutinib As a Promising Treatment for Pulmonary Complications Due to Refractory Chronic Graft Versus Host Disease**
İLHAN O., Seval G. C., UZAY A., KAYA E., Öztürk Z. N., DEVECİ B., YAVAŞOĞLU İ., Ural A. U., BEKÖZ H. S., AYLI M., et al.
Transplantation Cellular Therapy Meetings of ASTCT and CIBMTR, United States Of America, 8 - 12 February 2020, vol.26, pp.191
- IX. **Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions**
Pierre F., Ghulam J. M., Rena J B., Valeria S., Mara Dez C., Carlo F., Mario C., İLHAN O., Mikkael A S., Rami S K., et al.
ASH 2019, 7 - 10 December 2019
- X. **Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data**
CENGİZ SEVAL G., USLU A., KIRCALI E., CİVRİZ BOZDAĞ S., DALVA K., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., KUZU I., ARSLAN Ö., et al.
ASH 2019, 7 - 10 December 2019
- XI. **Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?**
KIRCALI E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., et al.
ASH 2019, 7 - 10 December 2019
- XII. **Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy**
Stephan S., Bosch F., Vronique L., İLHAN O., Jens K., Batrice M., Mikuskova E., Dzhelil O., Gianluigi R., Eugen T., et al.
ASH 2019, 7 - 10 December 2019
- XIII. **Hematologic Improvement–Neutrophil and –Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions**
Guillermo G., hulam J. M., Pierre F., Valeria S., Mara Dez C., Carlo F., Mario C., İLHAN O., Mikkael A S., Alan F L., et al.
ASH2019, 7 - 10 December 2019
- XIV. **Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis**
CENGİZ SEVAL G., ÖZTÜRK N., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., et al.

ASH 2019, 7 - 10 December 2019

- XV. **KRONİK MİYELOİD LOSEMİ (KML) HASTALARINDA KML KOKHUCRESİ BCR- ABL'DEN BAĞIMSIZ PROGNOSTİK BİR FAKTOR OLABİLİR Mİ?**
TOPRAK S. K., güven m., CENGİZ SEVAL G., DALVA K., İpek Ş., Okul N., Aral D., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.
45. ULUSAL HEMATOLOJİ KONGRESİ, Turkey, 30 October - 02 November 2019
- XVI. **YENİ TANI KLL HASTALARINDA TANI SIRASINDAKİ CD49DEKSPRESYONUNUN HASTALIĞA OZGU BAŞKA PARAMETRELERLEİLİŞKİSİ**
TOPRAK S. K., güven m., CENGİZ SEVAL G., DALVA K., İpek Ş., Okul N., Aral D., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.
45. Ulusal Hematoloji Kongresi, Turkey, 30 October - 02 November 2019
- XVII. **Kronik Myeloid Lösemi (KML) Hastalarında KML Kök Hücresi BCR-ABL' den Bağımsız Prognostik Bir Faktör Olabilir mi?**
İLHAN O., NARLI ÖZDEMİR Z., ARSLAN A., OKAY M., İPEK Ş., DALVA K., SAYDAM G., HAZNEDAROĞLU İ. C.
45. Ulusal Hematoloji Kongresi, Turkey, 30 October - 02 November 2019
- XVIII. **YAŞAM SÜRESİNİ VE KALİTESİNİ ETKİLEYEN DİRENÇLİ KGVHH TEDAVİSİNDE YENİ BİR YAKLAŞIMBTM İNHİBİTÖRÜ:GERÇEK YAŞAM VERİSİ**
İLHAN O., Seval G. C., UZAY A., KAYA E., DEVECİ B., YAVAŞOĞLU İ., URAL A. U., BEKÖZ H. S., AYLI M., SEVİNDİK Ö. G., et al.
45. Ulusal Hematoloji Kongresi, Turkey, 30 October - 02 November 2019
- XIX. **TÜRKİYE'DE PAROKSİSMAL NOKTÜRNAL HEMOGLOBİNÜRİDEN ŞÜPHELENİLEN HASTALARIN ÇOKMERKEZLİ TANISAL TARAMA ÇALIŞMASI**
İLHAN O., ÖZDEMİR Z. N., ÖZET G., FALAY M., YENEREL M. N., TUĞLULAR A. T., TURGUT M., GÜVENÇ B., ÜNAL A., AYYILDIZ M. O., et al.
45. Ulusal Hematoloji Kongresi, Antalya, Turkey, 30 October - 02 November 2019, pp.131-132
- XX. **TÜRKİYE'DE PAROKSİSMAL NOKTÜRNALHEMOGLOBİNÜRİDEN ŞÜPHELENİLEN HASTALARIN ÇOKMERKEZLİ TANISAL TARAMA ÇALIŞMASI**
İLHAN O., NARLI ÖZDEMİR Z., ÖZET G., falay m., YENEREL M. N., TUĞLULAR A. T., TURGUT M., GÜVENÇ B., ÜNAL A., AYYILDIZ M. O., et al.
45. Ulusal Hematoloji Kongresi, Turkey, 30 October - 02 November 2019
- XXI. **A retrospective single center experience with the generic of lenalidomide Rivelime (R) compared with original patented drug Revlimid (R)**
BEKSAÇ M., CENGİZ SEVAL G., KOYUN D., TOPÇUOĞLU P., YÜKSEL M., GÜRMAN G., İLHAN O.
Lymphoma and Myeloma Congress 2019, 23 - 26 October 2019
- XXII. **Negative Impact of High LDH at Diagnosis on OS, But Not PFS, Can Be Overcome by Autologous Stem Cell Transplantation**
CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., İLHAN O., et al.
17th International Myeloma Workshop, 12 - 15 September 2019
- XXIII. **Haploidentical stem cell transplantation may be an option for hematological malignancies in urgent conditions**
İLHAN O., CENGİZ SEVAL G., USLU A., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.
45th Annual Meeting of the European Society for Blood and Marrow Transplantation, 24 - 27 March 2019
- XXIV. **Clonal Plasma Cell Detection by High Sensitive Flow Cytometry in Aphaeresis Product is Poor Prognostic and not Increased by Use of Plerixafor Alone**
CENGİZ SEVAL G., USLU A., DALVA K., BAKANAY S., MERTER M., ŞAHİN U., İLHAN O., BEKSAÇ M.
45th Annual Meeting of the European Society for Blood and Marrow Transplantation, Frankfurt, Germany, 24 - 27 March 2019, vol.54, pp.496-497
- XXV. **Can the drugs used before autologous hematopoietic stem cell transplantation have impact on CMV reactivation that results in decreased os in myeloma patients after ASCT**

YÜKSEL M., CENGİZ SEVAL G., KİRCİLİ E., D, K., ÖZTÜRK C., NARLI ÖZDEMİR Z., ÇINAR G., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., et al.

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), 24 - 27 March 2019

XXVI. Is mobilization with chemotherapy effect response in the multiple myeloma?

CENGİZ SEVAL G., USLU A., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., AKAN H., et al.

45th Annual Meeting of the European Society for Blood and Marrow Transplantation, 24 - 27 March 2019

XXVII. Can Nelarabine Rescue The Graft After Allogeneic Hematopoietic Stem Cell Transplantation In T-All ?

YÜKSEL M., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., AKAN H., BEKSAÇ M., et al.

24th Congress of the European Hematology Association, 13 - 16 June 2019

XXVIII. Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients?

İLHAN O., CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., AKAN H., et al.

2019 American Society of Clinical Oncology (ASCO) Annual Meeting, 1 - 03 June 2019

XXIX. Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in myeloma patients undergoing autologous stem cell transplantation

DEMİRER T., CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., AKAN H., İLHAN O., et al.

2019 American Society of Clinical Oncology (ASCO) Annual Meeting, 1 - 03 June 2019

XXX. Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in myeloma patients undergoing autologous stem cell transplantation.

DEMİRER T., SEVAL G. C., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., AKAN H., İLHAN O., et al.

ASCO, 31 May - 03 June 2019

XXXI. RETROSPECTIVE ANALYSIS OF 149 UNSELECTED PATIENTS WITH MANTLE CELL LYMPHOMA CONFIRMS PROGNOSTIC RELEVANCE OF MIPI: SINGLE CENTER EXPERIENCE

CENGİZ SEVAL G., ULAŞ B. B., Bolat B., Taşçı O., Karatepe F., KUZU I., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

7th International Congress on Leukemia Lymphoma Myeloma, 3 - 04 May 2019

XXXII. LEUKAPHERESIS REDUCES 4-WEEK MORTALITY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH HYPERLEUKOCYTOSIS - A RETROSPECTIVE STUDY FROM A TERTIARY CENTER

CENGİZ SEVAL G., USLU A., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., et al.

7th International Congress on Leukemia Lymphoma Myeloma, 3 - 04 May 2019

XXXIII. PRE-TRANSPLANT HEMOGLOBIN AND SERUM CREATININE LEVELS CORRELATE WITH PROGRESSION FREE SURVIVAL IN MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., İLHAN O., AKAN H., et al.

7th International Congress on Leukemia Lymphoma Myeloma, 3 - 04 May 2019

XXXIV. CAN ELTROMBOPAG TREAT THE THROMBOCYTOPENIA AFTER STEM CELL TRANSPLANTATION

YÜKSEL M., KIRCALI E., CENGİZ SEVAL G., KOYUN D., USLU A., ÖZTÜRK C., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., BEKSAÇ M., et al.

7th International Congress on Leukemia Lymphoma Myeloma, 2 - 04 May 2019

XXXV. LEUKAPHERESIS REDUCES 4-WEEK MORTALITY IN ACUTEMYELOID LEUKEMIA PATIENTS WITH HYPERLEUKOCYTOSIS -A RETROSPECTIVE STUDY FROM A TERTIARY CENTER

SEVAL G. C., USLU A., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., et al.

7th International Congress on Leukemia Lymphoma Myeloma, 2 - 04 May 2019

- XXXVI. **CAN AUTOLOGOUS STEM CELL TRANSPLANTATION ABROGATE THE POOR PROGNOSIS ASSOCIATED WITH HIGH LDH?**
SEVAL G. C., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., İLHAN O., AKAN H., et al.
7th International Congress on Leukemia Lymphoma Myeloma, 2 - 04 May 2019
- XXXVII. **retrospective analysis of 149 unselected patients with mantle cell lymphoma confirms prognostic relevance of mipi: single center experience**
CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., İLHAN O., AKAN H., et al.
ICLLM 2019, 02 May 2019
- XXXVIII. **RETROSPECTIVE ANALYSIS OF 149 UNSELECTED PATIENTS WITH MANTLE CELL LYMPHOMA CONFIRMS PROGNOSTIC RELEVANCE OF MIPI: SINGLE CENTER EXPERIENCE**
SEVAL G. C., ULAŞ B. B., bolat b., Taşçı O., karatepe f., KUZU I., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.
7th International Congress on Leukemia Lymphoma Myeloma, 2 - 04 May 2019
- XXXIX. **Transplant Sonrası Trombositopenide Eltrombopag: Tek Merkez Deneyimiz**
KIRCALI E., CENGİZ SEVAL G., KOYUN D., CİVRİZ BOZDAĞ S., TOPÇUOĞLU P., ÖZCAN M., BEKSAÇ M., İLHAN O., ARSLAN Ö., GÜRMAN G., et al.
11. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedavileri Kongresi, Turkey, 1 - 03 March 2019
- XL. **Multiple Myelom Hastalarında Otolog Periferik Kök Hücre Nakli Esnasında Gelişen Nötropenik Ateş**
USLU A., CENGİZ SEVAL G., ÖZTÜRK C., NARLI ÖZDEMİR Z., KIRCALI E., KOYUN D., TOPÇUOĞLU P., TOPRAK S. K., CİVRİZ BOZDAĞ S., İLHAN O., et al.
11. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedavileri Kongresi, Turkey, 1 - 03 March 2019
- XLI. **Allojeneik Kök Hücre Nakli Sonrası Akut Lösemi Hastalarında Nüksü Öngörmede Kimerizm İle Mrd Karşılaştırılması**
CENGİZ SEVAL G., ULAŞ B. B., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., İLHAN O., et al.
11. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedavileri Kongresi, Turkey, 1 - 03 March 2019
- XLII. **İyi Riskli Aml'de İkinci Tam Remisyonda Allojeneik Hematopoietik Kök Hücre Nakli Tek Merkez Deneyimi**
PEKCAN G., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.
11. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedavileri Kongresi, Turkey, 1 - 03 March 2019
- XLIII. **POSTTRANSPLANT LENFOSİTOZ ÖNEMLİ BİR PARAMETRE MİDİR?**
CENGİZ SEVAL G., USLU A., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., AKAN H., et al.
11. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedavileri Kongresi, Turkey, 1 - 03 March 2019
- XLIV. **T-All Hastalarında Allojeneik Hematopoietik Kök Hücre Nakli Sonrasında Nelarabin Tedavisi Graftı Kurtarabilir mi?**
CENGİZ SEVAL G., USLU A., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., et al.
11. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedavileri Kongresi, Turkey, 1 - 03 March 2019
- XLV. **Refrakter Akut Lösemili Hastalarda Ardışık Kurtarma Tedavisi İle Birlikte Ahkhn Yeterli Kür Sağlayabilir mi?**
CENGİZ SEVAL G., KIRCALI E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., AKAN H., et al.
11. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedavileri Kongresi, Turkey, 1 - 03 March 2019
- XLVI. **Plerixafor, Periferik Kök Hücre Ürününde Akım Sitometri İle Saptanabilen Klonal Plazma Hücre Kontaminasyonunu Etkiler Mi?**
CENGİZ SEVAL G., USLU A., DALVA K., BAKANAY ÖZTÜRK Ş. M., MERTER M., ŞAHİN U., İLHAN O., BEKSAÇ M.
11. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedavileri Kongresi, Antalya, Turkey, 1 - 02 March 2019, pp.74-

- XLVII. Impact of ABO mismatch on outcomes of allogeneic hematopoietic stem cell recipients: 30 years of experience with 1016 patients.**
ATILLA E., TOPÇUOĞLU P., AKKUŞ E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., DEMİRER T., ARSLAN Ö., ÖZCAN M., İLHAN O., et al.
TCT Meetings of ASBMT and CIBMTR, February 20-24, 2019, Houston, Texas, USA. Biol Blood Marrow Transplant 201925(3):S322., 20 - 24 February 2019
- XLVIII. Akut Miyeloid Lösemide Nakil Öncesi Minimal Kalıntı Hastalık Diğer Risk Faktörlerinden Daha Önemli Midir?**
NARLI ÖZDEMİR Z., ŞAHİN U., BALTACI M. A., USLU A., ÖZTÜRK C., CENGİZ SEVAL G., DALVA K., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.
11. Ulusal Kemik İliği Transplantasyonu ve Hücresele Tedaviler Kongresi, Antalya, Turkey, 1 - 02 March 2019, pp.76-77
- XLIX. Impact of ABO mismatch on outcomes of allogeneic hematopoietic stem cell recipients: 30 years of experience with 1016 patients.**
ATILLA E., TOPÇUOĞLU P., AKKUŞ E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., DEMİRER T., ARSLAN Ö., ÖZCAN M., İLHAN O., et al.
TCT Meetings of ASBMT and CIBMTR, February 20-24, 2019, Houston, Texas, USA. Biol Blood Marrow Transplant 201925(3):S322., 20 - 24 February 2019, vol.25, pp.322
- L. Impact of ABO mismatch on outcomes of allogeneic hematopoietic stem cell recipients: 30 years of experience with 1016 patients.**
ATILLA E., TOPÇUOĞLU P., AKKUŞ E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., DEMİRER T., ARSLAN Ö., ÖZCAN M., İLHAN O., et al.
TCT Meetings of ASBMT and CIBMTR, February 20-24, 2019, Houston, Texas, USA. Biol Blood Marrow Transplant 201925(3):S322., 20 - 24 February 2019
- LI. MİYELOM HASTALARINDA OHKHN ÖNCESİ KULLANILAN İLAÇLARIN CMV REAKTİVASYONU ÜZERİNE SAĞKALIMI AZALTICI ETKİSİ OLABİLİR Mİ?**
YÜKSEL M., CENGİZ SEVAL G., USLU A., KIRCALI E., KOYUN D., ÖZTÜRK C., NARLI ÖZDEMİR Z., ÇINAR G., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.
11. Ulusal Kemik İliği Transplantasyonu ve Hücresele Tedaviler Kongresi, Turkey, 1 - 03 March 2019
- LII. CAN AUTOLOGOUS STEM CELL TRANSPLANTATION ABROGATE THE POOR PROGNOSIS ASSOCIATED WITH HIGH LDH?**
CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., İLHAN O., AKAN H., et al.
7th International Congress on Leukemia Lymphoma Myeloma, 3 - 04 May 2019
- LIII. Impact of ABO mismatch on outcomes of allogeneic hematopoietic stem cell recipients: 30 years of experience with 1016 patients.**
ATILLA E., TOPÇUOĞLU P., AKKUŞ E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., DEMİRER T., ARSLAN Ö., ÖZCAN M., İLHAN O., et al.
TCT Meetings of ASBMT and CIBMTR, February 20-24, 2019, Houston, Texas, USA. Biol Blood Marrow Transplant 201925(3):S322., 20 - 24 February 2019
- LIV. Impact of ABO mismatch on outcomes of allogeneic hematopoietic stem cell recipients: 30 years of experience with 1016 patients.**
ATILLA E., TOPÇUOĞLU P., AKKUŞ E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., DEMİRER T., ARSLAN Ö., ÖZCAN M., İLHAN O., et al.
TCT Meetings of ASBMT and CIBMTR, February 20-24, 2019, Houston, Texas, USA. Biol Blood Marrow Transplant 201925(3):S322., 20 - 24 February 2019
- LV. Influence of Conditioning Regimens with Total Body Irradiation (TBI) on Graft Versus Host Disease and Graft Versus Leukemia Effect Following Donor Lymphocyte Infusions (DLI)**
SEVAL G. C., ATILLA E., ULAŞ B. B., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.

Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR, 20 - 24 February 2019, vol.25, pp.176-177

- LVI. **İmmün Trombositopeni (İTP) hastalarında ABO kan gruplarının birinci basamak tedavi yanıtına etkisi**
AKKUŞ E., FİDAN Ç., KUŞTAŞ A. A., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.
TKBD Uluslararası Katılımlı Hematolojik Hastalıkların Tanı Ve İzleminde Laboratuvar Sempozyumu, Turkey, 5 - 07 April 2018, vol.16, pp.44
- LVII. **Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF**
DEMİRER T., AYLI M., ÖZCAN M., GÜNEL N., HAZNEDAR R., DAĞLI M., FEN T., GENÇ Y., DİNÇER S., ARSLAN Ö., et al.
BRITISH JOURNAL OF HAEMATOLOGY, 1 January - 30 December 2018, vol.116, pp.468-474
- LVIII. **Retrospective Analysis of 149 Unselected Patients with Mantle Cell Lymphoma Confirms Prognostic Relevance of Mantle Cell Lymphoma International Prognostic Index: Single Center Experience**
SEVAL G. C., ULAŞ B. B., Taşçı O., Özel F., Bulat B., KUZU I., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ÖZCAN M., et al.
60th ASH Annual Meeting, San Diego, United States Of America, 30 November - 05 December 2018
- LIX. **Comparison of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Center Institution Experience**
TOPÇUOĞLU P., SEVAL G. C., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DALVA K., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.
60th ASH Annual Meeting, san diego, United States Of America, 29 November - 05 December 2018, vol.132, pp.5776
- LX. **Donor Lymphocyte Infusions for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience**
GÜRMAN G., SEVAL G. C., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.
60th ASH Annual Meeting Exposition, san Diego, 29 November - 04 December 2018, vol.132, pp.4673
- LXI. **Residual Clonal Plasma Cells Detected by Flow Cytometry at 10⁻⁴ Level within Autologous Stem Cell Grafts is Associated with Significantly Less Overall Survival**
CENGİZ SEVAL G., DALVA K., BAKANAY S., MERTER M., ŞAHİN U., USLU A., ÖZTÜRK C., İLHAN O., BEKSAÇ M.
60th American Society of Hematology Annual Meeting, San Diego, CA, United States Of America, 1 - 04 December 2018, vol.132, pp.3438
- LXII. **Impact of ABO Mismatch on Outcomes of Allogeneic Hematopoietic Stem Cell Recipients: 30 Years of Experience with 1016 Patients**
ATİLLA E., TOPÇUOĞLU P., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., DEMİRER T., ÖZCAN M., BEKSAÇ M., İLHAN O., AKAN H., et al.
60th ASH Annual Meeting, 30 November - 05 December 2018
- LXIII. **The Outcome of Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation for Isolated CD4(+) T-cell Deficiency with Interleukin-2 Inducible T-cell Kinase (ITK) Gene Defect**
YÜKSEL M., NARLI ÖZDEMİR Z., ŞAHİN U., ÇAĞDAŞ AYVAZ D. N., TURKUM ATIKCAN D., SERTESEN E., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., et al.
44th Annual Meeting of European Society for Blood and Marrow Transplantation, Lisbon, Portugal, 18 - 21 March 2018, vol.53, pp.533-534
- LXIV. **İndüksiyon Mu Hazırlama Rejimi Mi Daha Önemli? İndüksiyon Sonrası Kalıntı Hastalığın Saptanamaması Bir Prognostik Gösterge Olabilir**
CENGİZ SEVAL G., BAKANAY ÖZTÜRK Ş. M., MERTER M., ŞAHİN U., USLU A., NARLI ÖZDEMİR Z., öztürk c., DALVA K., İLHAN O., BEKSAÇ M.
44. Ulusal Hematoloji Kongresi, Antalya, Turkey, 31 October - 03 November 2018, pp.161-162
- LXV. **Hematopoietik kök hücre nakli için toplanan kemik iliği materyallerinde sayılan cd34 pozitif hücreler: Cd34 pozitif gen hematogonlara dikkat**
DALVA K., Öz m. d., hakkoloğlu ş., avcu f., ERTEM M., İLHAN O., GÜRMAN G.

44. ulusal hematoloji kongresi, Turkey, 31 October - 03 November 2018
- LXVI. **ALLOJENİK HEMATOPOİETİK KÖK HÜCRE NAKLİ YAPILAN ALL HASTALARINDA CMV ENFEKSİYONUNUN NAKİL SONUÇLARINA ETKİLERİ**
KALACI E., ŞAHİN EROĞLU D., CENGİZ SEVAL G., NARLI ÖZDEMİR Z., BEKSAÇ M., ÖZCAN M., ARSLAN Ö., İLHAN O., TOPÇUOĞLU P., GÜRMAN G., et al.
44. Ulusal Hematoloji Kongresi, Turkey, 31 October - 03 November 2018
- LXVII. **Hematopoietik kök hücre nakli için toplanan kemik iliği materyallerinde sayılan Cd34 pozitif hücreler: CD34pozitif genç hematogonlara dikkat**
DALVA K., Öz m. d., hakkoloğlu ş., ipek ş., öztürk a., taşkır f., okul n., ayyıldız e., avcu f., ERTEM M., et al.
44. ulusal hematoloji kongresi, Turkey, 31 October - 03 November 2018
- LXVIII. **ALLOJENİK HEMATOPOİETİK KÖK HÜCRE NAKLİ YAPILAN ALL HASTALARINDA CMV ENFEKSİYONUNUN NAKİLSONUÇLARINA ETKİLERİ**
KALACI E., ŞAHİN EROĞLU D., CENGİZ SEVAL G., NARLI ÖZDEMİR Z., BEKSAÇ M., ÖZCAN M., ARSLAN Ö., İLHAN O., TOPÇUOĞLU P., GÜRMAN G., et al.
44. Ulusal Hematoloji Kongresi, Turkey, 31 October - 03 November 2018
- LXIX. **Promising utilization areas of theurapeutic plasmapheresis in cardiovascular surgery practice**
DURDU M. S., ÇAKICI M., GÜMÜŞ F., ÇUBUKÇUOĞLU DENİZ G., CİVRİZ BOZDAĞ S., DİKMEN YAMAN N., İLHAN O., UÇANOK K.
Türk Kalp ve Damar Cerrahisi Derneği 15. Kongresi, Turkey, 26 - 29 October 2018, vol.26
- LXX. **Yüksek PRA Düzeyi Olan Böbrek Nakli Alıcılarında Plazmaferez , IVIG ve Ritüksimab Tedavisinin Etkinliği**
ORS SENDOGAN D., SARITAŞ H., KUMRU G., İLHAN O., TÜZÜNER A., KEVEN K., ŞENGÜL Ş.
Ulusan Nefroloji, Hipertansiyon, Diyaliz ve tRansplantasyon Kongresi, Antalya, Turkey, 3 - 07 October 2018
- LXXI. **AKUT LÖSEMİ HASTALARINDA HLA UYUŞUMSUZLUĞUNUN NAKİL SONUÇLARINA ETKİSİ: TEK MERKEZ DENEYİMİ**
CENGİZ SEVAL G., NARLI ÖZDEMİR Z., TATAR L., SÖKMEN M., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DALVA K., ARSLAN Ö., ÖZCAN M., et al.
44. Ulusal Hematoloji Kongresi, Turkey, 31 October - 03 November 2018
- LXXII. **Retrospective analysis of 115 unselected patients with mantle cell lymphoma: Single center experience**
Cengiz Seval G., BULAT B., Ozel F., Tasci O., Kuzu I., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ÖZCAN M., et al.
ASCO Annual Meeting 2018, 1 - 05 June 2018, vol.36, pp.19525
- LXXIII. **Akut karaciğer yetmezliğinde plazmaferezin etkinliği**
SANDAL S., ZEYBEK İ., TUNA KIRSAÇLIOĞLU C., ALTUNTAŞ C., DEMİR E., KENDİRLİ T., İLHAN O., KULOĞLU Z., TANCA A.
12.Ulusal Çocuk Gastroenteroloji, Hepatoloji ve BESLENME KONGRESİ, Turkey, 18 - 21 April 2018
- LXXIV. **Heparin enhances CD34 content of stem cells collected following G-CSF +/- chemotherapy**
MERTER M., ŞAHİN U., YILDIRIM Y., İLHAN O., BEKSAÇ M.
44th Annual Meeting of European Society for Blood and Marrow Transplantation, Lizbon, Portugal, 18 - 21 March 2018
- LXXV. **Fit Elderly Patients with aggressive lymphoma do not need dose reduction of conditioning regimen**
İLHAN O., CENGİZ SEVAL G., USLU A., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.
44th Annual Meeting of the European Society for Blood and Marrow Transplantation, 18 - 21 March 2018
- LXXVI. **Impact of Hepatitis B Core Antibody Seopositivity on the Liver Function Tests after Autologous Hematopoietic Stem Cell Transplantation For Multiple Myeloma**
CENGİZ SEVAL G., SERTESEN E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., et al.
44th Annual Meeting of the European Society for Blood and Marrow Transplantation, 18 - 21 March 2018
- LXXVII. **Blastic Plasmacyto Id Dendritic Cell Neoplasm: Single CenterExperience on a Rare Hematological**

Malignancy

NARLI ÖZDEMİR Z., SEVAL G. C., USLU A., GÜNDÜZ M., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., KUZU I., ÖZCAN M., GÜRMAN G., et al.

5th Aegean Hematology Oncology Symposium, Greece, 23 September 2018

LXXVIII. Donor lymphocyte infusion after salvage chemotherapy in relapsed acute myeloblastic leukemia patients after allogeneic stem cell transplantation

USLU A., SEVAL G. C., CİVRİZ BOZDAĞ S., GÜRMAN G., DEMİRER T., ARSLAN Ö., ÖZCAN M., TOPRAK S. K., TOPÇUOĞLU P., İLHAN O.

The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Poster Sessions, Lisbon, Portugal, 18 - 21 March 2018

LXXIX. ALLOJENEİK KÖK HÜCRE NAKLİ SONRASI GELİŞEN KARACİĞER SİNÜZOİDAL TIKANIKLIK SENDROM İNSİDANSIVE KLİNİK BULGULAR

GÜNDÜZ M., ATILLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., AKAN H., et al.

10. ULUSAL KEMİK İLİĞİ TRANSPLANTASYONU VE HÜCRESEL TEDAVİLER KONGRESİ, Antalya, Turkey, 1 - 03 March 2018

LXXX. Allojeneik Hematopoetik Kök Hücre Nakli Sonrası Akut Myeloid Lösemi Nüksünün Yönetimi ve Prognuzu

ŞAHİN U., GÜNDÜZ M., MERTER M., NARLI ÖZDEMİR Z., ÖZEN M., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., ARSLAN Ö., ÖZCAN M., et al.

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Turkey, 1 - 03 March 2018, pp.126-127

LXXXI. Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies

ARSLAN Ö., ELÇİN A. E., ATILLA E., Şeker Ş., Baydın P., Gündüz M., ÖZEN M., Bayraktar U., İLHAN O., BEKSAÇ M., et al.

ASBMT 2018, 21 - 25 February 2018, vol.24, pp.152-153

LXXXII. Ph Negatif ALL'de 1. Tam Remisyonda Yapılan Pekiştirme Tedavileri Nakil Sonrası Başarıyı Arttırır
NARLI ÖZDEMİR Z., ŞAHİN U., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., DEMİRER T., AKAN H., İLHAN O., et al.

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Turkey, 1 - 03 March 2018, pp.107-108

LXXXIII. Age is Not an Important Factor for Autologous Peripheral Hematopoietic Stem Cell Mobilization and Collection in Patients with Multiple Myeloma

İLHAN O., CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., AKAN H., et al.

2018 BMT Tandem Meetings, 21 - 25 February 2018, vol.24, pp.140

LXXXIV. Retrospective Analysis Learn Conditioning for Autologous Stem Cell Transplantation

SOYDAN E., GÖKMEN A., İLHAN O., ARSLAN Ö., ÖZCAN M.

Blood @marrow transplant Res, 21 - 25 February 2018

LXXXV. Dilemma-High Response Rates Vs High Toxicity: Autologous Stem Cell Transplantation for Lymphoma

ATILLA E., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., AKAN H., ARSLAN Ö., DEMİRER T., BEKSAÇ M., İLHAN O., et al.

American Society of Hematology, 8 - 12 December 2017

LXXXVI. Age Is Not Important for Autologous Peripheral Hematopoietic Stem Cell Transplantation in Multiple Myeloma

İLHAN O., GÜLDANE C., TOPRAK S. K., TOPÇUOĞLU P., ÖZEL F., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.

American Society of Hematology, 8 - 12 December 2017

LXXXVII. Hematolojik Maligniteli Hastalarda Haploidentik Kök Hücre Nakillerinde Mezenkimal Kök Hücre

Uygulamas1

ARSLAN Ö., ELÇİN A. E., ATILLA E., ŞEKER Ş., BAYDIN P., GÜNDÜZ M., ÖZEN M., BAYRAKTAR U. D., İLHAN O., BEKSAÇ M., et al.

43. Ulusal Hematoloji Kongresi, Antalya, Turkey, 1 - 04 November 2017

LXXXVIII. Hematolojik Maligniteli Hastalarda Haploidentik Kök Hücre Nakillerinde Mezenkimal Kök Hücre Uygulaması.

ARSLAN Ö., ELÇİN A. E., ATILLA E., ŞEKER Ş., BAYDIN P., GÜNDÜZ M., ÖZEN M., BAYRAKTAR U. D., İLHAN O., BEKSAÇ M., et al.

43.ULUSAL HEMATOLOJİ KONGRESİ, Turkey, 1 - 04 November 2017

LXXXIX. Engrafmanın Erken Belirteci: Büyük Boyanmamış Hücreler

Aydın T., MERTER M., ŞAHİN U., Pekcan G., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

43. Ulusal Hematoloji Kongresi, Antalya, Turkey, 1 - 04 November 2017, pp.53

XC. İmmun Trombositopenide (İTP) Yenilikler Işığında Klinik Retrospektif Değerlendirme: Tek Merkez Deneyimi

AKKUŞ E., KUŞTAŞ A. A., PEKCAN G., MERTER M., ŞAHİN U., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

43. Ulusal Hematoloji Kongresi, Antalya, Turkey, 1 - 04 November 2017, pp.98-99

XCI. OTOLOG PERİFERİK KÖK HÜCRE NAKLİNDE KÖK HÜCRESAKLANMA SÜRESİ ENGRAFMAN SÜRESİNİ ETKİLER Mİ?

MERTER M., Güleç B., Özcan G., Zehra Özdemir Z., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., DEMİRER T., ÖZCAN M., et al.

43. Ulusal Hematoloji Kongresi, Antalya, Turkey, 1 - 04 November 2017, pp.220

XCII. TÜRKİYE'DE PAROKSİSMAL NOKTÜRNALHEMOGLOBİNÜRİDEN ŞÜPHELENİLEN HASTALARIN SIKLIĞININ SAPTANMASINA YÖNELİK ÇALIŞMA

İLHAN O., ÖZET G., FALAY M., YENEREL M. N., TURGUT M., ÜNAL A., AYYILDIZ M. O., HACIHANEFİOĞLU A., SAYDAM G., ŞENCAN M., et al.

43. Ulusal Hematoloji Kongresi, Turkey, 1 - 05 November 2017

XCIII. Türkiye'den Çok Merkezli Erken Erişim Program Sonuçları: Daha Önce Yoğun Tedavi Almış Relaps/Refrakter Multipl Miyelom Hastalarında Daratumumabın Etkililik ve Güvenliliği

BEKSAÇ M., GOKER H., TURGUT M., AYDIN Y., BESİSİK S., Cagırgan S., Tuğlular T., Vural F., Yagci M., ALACACIOĞLU İ., et al.

Türk Hematoloji Derneği, Turkey, 17 - 20 August 2017

XCIV. Evaluating peritransplant albumin decline as a predictor of acute graft versus host disease

MERTER M., YÜKSEL M., demir e., ŞAHİN U., CİVRİZ BOZDAĞ S., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., et al.

43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, Marseille, France, 26 - 29 March 2017, vol.52, pp.210-211

XCIV. The outcome of haploidentical hematopoietic celltransplantations

ATILLA E., bilgiç e., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., İLHAN O., ÖZCAN M., GÜRMAN G.

43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, 26 - 29 March 2017, vol.52, pp.314

XCVI. Peripheral blood stem cell mobilization and collection from elderly patients (≥65 years) with multiple myeloma: A single center experience

seval g. c., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., AKAN H., et al.

43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, 26 - 29 March 2017, vol.52

XCVII. peripheral blood stem cell mobilization and collection from elderly patients with multiple myeloma: A single center experience

seval g., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN

G., AKAN H., et al.

ebmt 2017, 26 - 29 March 2017

- XCVIII. Allogeneic hematopoietic stem cell transplantation(allo-HSCT) in advanced age adults: is it possible to transplant safely?**
ATILLA E., BAŞ O., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., AKAN H., GÜRMAN G., ÖZCAN M., BEKSAÇ M., et al.
43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, 26 - 29 March 2017, vol.52, pp.272-273
- XCIX. ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADVANCED AGE ADULTS: IS IT POSSIBLE TO TRANSPLANT SAFELY?**
ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., AKAN H., GÜRMAN G., ÖZCAN M., BEKSAÇ M., ARSLAN Ö., et al.
ebmt2017, 26 - 29 March 2017
- C. The outcome of haploidentical stem cell transplantation**
ATILLA E., BILGIÇ E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., İLHAN O., ÖZCAN M., GÜRMAN G.
ebmt 2017, 22 - 25 June 2017
- CI. AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MANTLE CELL LYMPHOMA: SINGLE CENTER EXPERIENCE**
TOPRAK S. K., ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., DEMİRER T., ÖZCAN M., ARAT M., İLHAN O., et al.
22nd Congress of the European-Hematology-Association, 22 - 25 June 2017
- CII. Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: A Single Center Experience**
TOPRAK S. K., ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., DEMİRER T., ARSLAN Ö., ÖZCAN M., ARAT M., et al.
Experience 22nd Congress of the European Hematology Association, 22 June - 25 May 2017
- CIII. A single center experience with two decades of follow-up on patients with hairy cell leukemia.**
İLHAN O., ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., DEMİRER T., ARSLAN Ö., AKAN H., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 2 - 06 June 2017
- CIV. Age as a decision factor for doing autologous stem cell transplantation in fit patients with myeloma and lymphoma**
İLHAN O., ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., AKAN H., et al.
53rd Annual Meeting, 2 - 06 June 2017
- CV. Comparison of myeloablative vs reduced intensity conditioning regimens in stem cell transplantation for acute myeloid leukemia**
GÜRMAN G., AYDEMİR GÜLOKSUZ G., ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ÖZCAN M., ARSLAN Ö., et al.
leukemia 53rd Annual Meeting, 2 - 06 June 2017
- CVI. Allogeneic stem cell transplantation results in our myelodysplastic syndrome (MDS) patients**
GÜRMAN G., ATACA ATILLA P., AYDIN T., ATILLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ÖZCAN M., DEMİRER T., et al.
patients 53rd Annual Meeting Jun 2-6, 2017, 2 - 06 June 2017
- CVII. A single center experience With two decades of follow-up on patients With hairy cell leukemia**
İLHAN O., ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., DEMİRER T., ARSLAN Ö., ÖZCAN M., et al.
3rd Annual Meeting Jun 2-6, 2017, 2 - 06 June 2017
- CVIII. Large Unstained Cell Percentage as a Predictor of Efficacious Peripheral Stem Cell Mobilization**
MERTER M., KÖKEN K., YÜKSEL M., NURDAN DEMİR E., ŞAHİN U., CİVRİZ BOZDAĞ S., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.

6th International Congress on Leukemia Lymphoma Myeloma, 11 - 13 May 2017

- CIX. **A biosimilar G-CSF filgrastim is as effective as a reference drug, however, it is not as cost effective as it supposed to be**
PEKCAN G., KURT YÜKSEL M., ŞAHİN U., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., İLHAN O., DEMİRER T., et al.
6th International Congress on Leukemia Lymphoma Myeloma, Antalya, Turkey, 11 - 13 May 2017, pp.112
- CX. **Evalauting peritransplant albümin decline as a predictor os acute graft versus host disease**
MERTER M., YÜKSEL M., NURDAN DEMİR E., ŞAHİN U., CİVRİZ BOZDAĞ S., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., et al.
43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, 26 - 29 March 2017
- CXI. **Allogeneic Hematopoietic Stem Cell Trnasplantation (Allo-HSCT) in advanced age adults:Is it possible to transplant safely?**
ATİLLA E., BAŞ Ö., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., AKAN H., GÜRMAN G., ÖZCAN M., TOPÇUOĞLU P., et al.
43rd Annual Meeting Of EBMT, 26 - 29 March 2017
- CXII. **Large Unsaturated Cell (LUC) percentage as a predictor of efficacious peripheral stem cell mobilization in autologous stem cell transplantation**
MERTER M., KÖKEN K., YÜKSEL M., DEMİR N., ŞAHİN U., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.
43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, 26 - 29 March 2017
- CXIII. **Herpes SimplexVirus infection in patients after allogeneic hematopoietic stem cell transplantation**
ATİLLA E., ÖZEL F., YILMAZ V., ATACA ATİLLA P., ATEŞAĞAOĞLU B., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., AKAN H., et al.
43rd Annual Meeting Of EBMT, 26 - 29 March 2017
- CXIV. **Peripheral Blood Stem Cell Mobilization and collection from elderly patients 65 years with multipl myeloma: A , single center exprience**
CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., İLHAN O., ÖZCAN M., GÜRMAN G., BEKSAÇ M., et al.
43rd Annual Meeting Of EBMT, 26 - 29 March 2017
- CXV. **The outcome of Haploidentical Hematopoietic Celll Trnasplantations (Haplo HSCT)**
ATİLLA E., ECE B., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., İLHAN O., ÖZCAN M., GÜRMAN G.
43rd Annual Meeting Of EBMT, 26 - 29 March 2017
- CXVI. **Acute GVHD and untreated/haploidentical Trnasplants increses the incidence of hemorrhagic cystitis in Allo- HSCT Recipients**
TOPÇUOĞLU P., ATİLLA E., ATACA ATİLLA P., USLU A., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., DEMİRER T., ARSLAN Ö., ÖZCAN M., et al.
43rd Annual Meeting Of EBMT, 26 - 29 March 2017
- CXVII. **Management and Outcome of Central Nerve System(CNS) Involvement in Acute Lymphoblastic Leukemia**
ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., AKAN H., BEKSAÇ M., İLHAN O., GÜRMAN G.
BMT Tandem Meetings, orlando, United States Of America, 22 - 26 February 2017, vol.23, pp.251
- CXVIII. **Management and Outcome of Central Nervous System (CNS) Involvement in Acute Lymphoblastic Leukemia (ALL)**
ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., AKAN H., BEKSAÇ M., İLHAN O., GÜRMAN G., et al.
BMT Tandem Meetings, 22 - 26 February 2017
- CXIX. **Catheter Thrombosis in Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) Recipients**
GÜRMAN G., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.

BMT Tandem Meetings, 22 - 26 February 2017

- CXX. **Allogeneic stem cell transplantation for chronic lymphocytic Leukemia**
ATILLA E., ATACA ATILLA P., PEKCAN G., İLHAN O., GÜRMAN G., ÖZCAN M., ARSLAN Ö.
BMT TANDEM MEETINGS, 22 - 26 February 2017
- CXXI. **Does Hypogammaglobulinemia at Diagnosis Effects Survival and Infection Risk in Chronic Lymphocytic Leukemia CLL**
ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., İLHAN O., ÖZCAN M., ARSLAN Ö.
ASH, 3 - 06 December 2016
- CXXII. **Comparison of Reduced Intensity Conditioning RIC Regimen and Myeloablative Conditioning MAC Regimen in Allogeneic Hematopoietic Stem Cell Transplantation Allo HSCT for Adult Patients with Acute Leukemia**
GÜRMAN G., AYDEMİR GÜLÖKSÜZ G., ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.
ASH, 3 - 06 December 2016
- CXXIII. **AKUT MYELOİD LÖSEMİDE FLOW SİTOMETRİ İLE İNDÜKSİYON SONRASI TESPİT EDİLEN CD34 HÜCRE SAYISI SAĞKALIM VE RELAPSI ETKİLER**
ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., TOPRAK S. K., ARSLAN Ö., BEKSAÇ M., ÖZCAN M., İLHAN O., et al.
42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- CXXIV. **ALLOJENEİK KÖK HÜCRE NAKLİ OLAN AKUT LÖSEMİLERDE HAZIRLIK REJİMLERİNİN KARŞILAŞTIRILMASI**
GÜLÖKSÜZ G. A., ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.
42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- CXXV. **KRONİK LENFOSİTİK LÖSEMİ DE TANI ANINDA HİPOGAMAGLOBULİNEMİ SAĞKALIM VE ENFEKSİYON RİSKİ ÜZERİNDE ETKİLİ MİDİR**
ATACA ATILLA P., ATILLA E., PEKCAN G., TOPRAK S. K., TOPÇUOĞLU P., AKAN H., BEKSAÇ M., İLHAN O., ÖZCAN M., ARSLAN Ö., et al.
42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- CXXVI. **ALLOJENEİK KÖK HÜCRE NAKLİ YAPILAN HASTALARDA PERİTRANSPLANT ALBUMİN DÜŞÜŞÜ İLE GVHD İLİŞKİSİ**
MERTER M., ŞAH F. T., ŞAHİN U., YALÇINER M., KOCABAY H. E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., TOPRAK S. K., ARSLAN Ö., et al.
42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- CXXVII. **TROMBOTİK MİKROANJİOPATİDE TERAPÖTİK PLAZMA DEĞİŞİMİ**
ATILLA E., ATACA ATILLA P., TOPRAK S. K., TOPÇUOĞLU P., YÜKSEL M., CİVRİZ BOZDAĞ S., ARSLAN Ö., DEMİRER T., AKAN H., BEKSAÇ M., et al.
42. Ulusal Hematoloji, Turkey, 19 - 22 October 2016
- CXXVIII. **MYELODİPLASTİK SENDROM HASTALARININ OGATA SKORLAMASI İLE FLOW SİTOMETRİK OLARAK DEĞERLENDİRİLMESİ**
ATILLA E., ATACA ATILLA P., TÜREDİ Ö., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., AKAN H., BEKSAÇ M., ARSLAN Ö., ÖZCAN M., et al.
42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- CXXIX. **GRAFT VERSUS HOST HASTALIĞINDA EKSTRAKORPORAL FOTOFEREZİN YERİ**
GÜNDÜZ M., ATILLA E., ATACA ATILLA P., AKAY B. N., ŞANLI H., TOPÇUOĞLU P., İLHAN O., GÜRMAN G.
42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- CXXX. **ALLOJENEİK KÖK HÜCRE NAKİL ÖNCESİ FAZLA KİLOLU OBEZ OLMANIN SAĞKALIM VE NÜKS İLE İLİŞKİSİ**
ATILLA E., ATACA ATILLA P., CEYLAN A., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., AKAN H., BEKSAÇ M., ARSLAN Ö., et al.
42. ULUSAL HEMATOLOJİ KONGRESİ, Turkey, 19 - 22 October 2016

- CXXXI. **ALLOJENEİK KÖK HÜCRE NAKLİ HASTALARIMIZDAGELİŞEN KATATER TROMBOZLARI**
ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., TOPÇUOĞLU P., TOPRAK S. K., YÜKSEL M., YALÇINER M., SEVAL CENGİZ G., ARSLAN Ö., ÖZCAN M., et al.
42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- CXXXII. **PRİMER MYELOFİBROZİS TE ALLOJENEİK KÖKHÜCRE NAKLİ TEK MERKEZ DENEYİMİ**
CENGİZ G. S., GÜNDÜZ M., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., İLHAN O., ÖZCAN M.
42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- CXXXIII. **AKUT LENFOSİTİK LÖSEMİDE ALL SANTRAL SİNİRSİSTEMİ SSS TUTULUMUNA YAKLAŞIM**
ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., AKAN H., İLHAN O., GÜRMAN G., ÖZCAN M.
42.Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- CXXXIV. **PERİFERİK T HÜCRELİ LENFOMALARDA OTOLOGHEMATOPOETİK KÖK HÜCRE TRANSPLANTASYONU TEK MERKEZ DENEYİMİ**
ŞAHİN U., MERTER M., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., YÜKSEL M., ÖZCAN M., DEMİRER T., GÜRMAN G., et al.
42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- CXXXV. **Anti HLA Antikor Varlığının Allojeneik Kök Hücre Nakli Yapılan Hastalarda Engrafman Üzerine Etkisi: Tek Merkez Deneyimi**
MERTER M., AYDOĞAN M., TEKEŞ M. A., ŞAHİN U., AYYILDIZ Ö. M., KOCABAY H. E., TOPRAK S. K., TOPÇUOĞLU P., YÜKSEL M., CİVRİZ BOZDAĞ S., et al.
42. Ulusal Hematoloji Kongresi, Antalya, Turkey, 19 - 22 October 2016, pp.60-61
- CXXXVI. **BEING OVERWEIGHT PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION IS RELATED TO BETTER SURVIVAL**
ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., AKAN H., BEKSAÇ M., ARSLAN Ö., İLHAN O., ÖZCAN M., et al.
78.th Annual Meeting of the Japanese Society of Hematology, 13 - 15 October 2016
- CXXXVII. **IS IT POSSIBLE TO DIAGNOSE LOW RISK MYELODYSPLASTIC SYNDROME MDS BY FLOW CYTOMETRY**
ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., AKAN H., BEKSAÇ M., ARSLAN Ö., TOPÇUOĞLU P., ÖZCAN M., İLHAN O., et al.
EHA, 9 - 12 June 2016
- CXXXVIII. **OUR APPROACH TO HAIRY CELL LEUKEMIA HCL 31 YEARS OF EXPERIENCE**
ATACA ATİLLA P., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., AKAN H., ÖZCAN M., İLHAN O.
EHA, 9 - 12 June 2016
- CXXXIX. **CD34 POSITIVE CELL COUNT DETECTED BY MULTI COLOR FLOW CYTOMETRY MFC AFTER FIRST INDUCTION THERAPY IN ACUTE MYELOID LEUKEMIA AML EFFECTS ON SURVIVAL AND RELAPSE**
ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., İLHAN O., AKAN H., DALVA K., et al.
EHA, 9 - 12 June 2016
- CXL. **MANAGEMENT AND OUTCOME OF CENTRAL NERVOUS SYSTEM CNS INVOLVEMENT IN ACUTE LYMPHOBLASTIC LEUKEMIA ALL PRE AND POST TRANSPLANT** Conference 21st Congress of the European Hematology Association Location Copenhagen DENMARK
ATACA ATİLLA P., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., AKAN H., BEKSAÇ M., İLHAN O., GÜRMAN G., et al.
21st Congress of the European-Hematology-Association Location: Copenhagen, DENMARK, 9 - 12 June 2016, vol.101
- CXLI. **BEING OVERWEIGHT OBESE PRIOR TO ALLOJENEİK HEMATOPOIETIC STEM CELL TRANSPLANTATION ALLO HSCT IS RELATED TO BETTER OVERALL SURVIVAL OS AND DECREASED NON RELEASE MORTALITY**
ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., AKAN H., BEKSAÇ M., İLHAN O., ARSLAN Ö., ÖZCAN M.

EHA, 9 - 12 June 2016

- CXLII. EXTRACORPOREAL PHOTOPHERESIS SAFE AND EFFECTIVE FOR THE TREATMENT OF MYCOSIS FUNGOIDES**
ATILLA E., ATACA ATILLA P., CIVRİZ BOZDAĞ S., TOPRAK S. K., AKAY B. N., ŞANLI H., TOPÇUOĞLU P., AKAN H., GÜRMAN G., İLHAN O., et al.
EHA, 9 - 12 June 2016
- CXLIII. THROMBOSIS IN PAROXYSMAL NOCTURNAL HEMOGLOBULINURIA PATIENTS SINGLE CENTER EXPERIENCE**
MERTER M., ŞAHİN U., GÜNDÜZ M., NARLI ÖZDEMİR Z., CIVRİZ BOZDAĞ S., İLHAN O.
24th Biennial International Congress on Thrombosis / EMLTD Congress, 4 - 07 May 2016
- CXLIV. THERAPEUTIC THROMBOCYTAPHERESIS HIGHER PLATELET COUNTS SHOULD MATTER**
NARLI ÖZDEMİR Z., ŞAHİN U., CIVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ÖZCAN M., ARSLAN Ö., DEMİRER T., BEKSAÇ M., et al.
24th Biennial International Congress on Thrombosis / EMLTD Congress, 4 - 07 May 2016
- CXLV. ARE AGE AND JAK2V617F MUTATION RELATED TO THROMBOSIS IN CHRONIC MYELOPROLIFERATIVE DISEASES**
ATACA ATILLA P., ATILLA E., CIVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., AKAN H., ARSLAN Ö., ÖZCAN M., BEKSAÇ M., GÜRMAN G., et al.
24th Biennial International Congress on Thrombosis / EMLTD Congress, 4 - 07 May 2016
- CXLVI. THERAPEUTIC PLASMA EXCHANGE FOR THROMBOTIC MICROANGIOPATHY**
ATILLA E., ATACA ATILLA P., ŞAHİN U., CIVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., DEMİRER T., ÖZCAN M., et al.
24th Biennial International Congress on Thrombosis / EMLTD Congress, 4 - 07 May 2016
- CXLVII. Age as a decision factor for doing autologous stem cell transplantation in fit patients with myeloma and lymphoma**
İLHAN O., ATILLA E., ATACA ATILLA P., CIVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., YÜKSEL M., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.
ASCO, 3 - 07 June 2016
- CXLVIII. Effect of Cytomegalovirus Reactivation on Prognosis After Allogeneic Transplantation for Acute Leukemia with Active Disease Conditioned with a Sequential Regimen and Anti Thymocyte Globulin**
GÜNDÜZ M., YÜKSEL M., ŞAHİN U., MERTER M., NARLI ÖZDEMİR Z., CIVRİZ BOZDAĞ S., TOPRAK S. K., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.
42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, 3 - 06 April 2016
- CXLIX. THE EFFICACY OF TYROSINE KINASE INHIBITORS WITH STEROID IN Ph ACUTE LYMPHOBLASTIC LEUKEMIA**
GÜRMAN G., MERTER M., ATILLA E., ŞAHİN U., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., İLHAN O.
ASCO, 3 - 07 June 2016
- CL. Succesfull treatment in primary central nervous system lymphoma**
ATILLA E., ATACA ATILLA P., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., İLHAN O., GÜRMAN G., ÖZCAN M.
ASCO, 3 - 07 June 2016
- CLI. AKTİF HASTALIKLI AKUT LÖSEMİDE ATG VEHAZIRLIK REJİMİ İLE ALLOJENİK NAKİL SONRASICMV REAKTİVASYONUNUN PROGNOZA ETKİSİ**
GÜNDÜZ M., ŞAHİN U., MERTER M., NARLI ÖZDEMİR Z., CIVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., et al.
9.Ulusal Kemik İliği Transplantasyonu ve Kök Hücre Tedavileri Kongresi, Turkey, 3 - 05 March 2016
- CLII. PAROKSİSMAL NOKTÜRNAL HEMOGLOBİNÜRİHASTALARINDA ALLOJENEİK HEMATOPOETİK KÖKHÜCRE NAKLİ TEK MERKEZ DENEYİMİ**
NARLI ÖZDEMİR Z., TOPRAK S. K., TOPÇUOĞLU P., ŞAHİN U., GÜNDÜZ M., ATILLA E., ATACA ATILLA P., CIVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., et al.
9.Ulusal Kemik İliği Transplantasyonu ve Kök Hücre Tedavileri Kongresi, Turkey, 3 - 05 March 2016
- CLIII. Efficacy of High Dose Corticosteroid Premedication for the Prevention of Anti thymocyte Globulin**

Related Side Effects

MERTER M., ŞAHİN U., ATILLA E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.

42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation Location, 1 - 02 March 2016

- CLIV. **Clinical Characteristics and Frequency of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation**
ŞAHİN U., YÜKSEL M., MERTER M., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.
42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, Cyprus (Kktc), 1 - 02 March 2016
- CLV. **Safety and Efficacy of Obinutuzumab Plus Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia Subgroup Analysis of the Green Study**
İLHAN O.
blood journal, 3 - 05 December 2015
- CLVI. **NILOTINIB RESULTS IN IMPROVED RATES OF MOLECULAR RESPONSE IN TURKISH NEWLY DIAGNOSED CML CP PATIENTS A 24 MONTH UPDATE**
SAYDAM G., HAZNEDAROĞLU İ. C., İLHAN O., KAYNAR L., ALI R., GÜVENÇ B., AKAY O. M.
HAEMATOLOGICA, 11 - 14 June 2015
- CLVII. **MULTICENTER RETROSPECTIVE ANALYSIS OF TURKISH PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS**
İLHAN O., SAYDAM G., HAZNEDAROĞLU İ. C., ÜNAL A., UĞUR BİLGİN A.
HAEMATOLOGICA, 11 - 14 June 2015
- CLVIII. **Does chronic lymphocytic leukemia occur in younger adults in Turkey**
ARSLAN Ö., TOPÇUOĞLU P., ATILLA E., ÖZCAN M., CİVRİZ BOZDAĞ S., TOPRAK S. K., İLHAN O., PEKCAN G.
JOURNAL OF CLINICAL ONCOLOGY, 29 May - 02 June 2015
- CLIX. **Allogeneic stem cell transplantation results in our myelodysplastic syndrome MDS patients**
ATACA P., İLHAN O., ARSLAN Ö., TOPÇUOĞLU P., ATILLA E., AKAN H.
JOURNAL OF CLINICAL ONCOLOGY, 29 May - 02 June 2015
- CLX. **Azacitidine in combination with ATRA valproic acid in elderly AML patients**
ÖZCAN M., CİVRİZ BOZDAĞ S., İLHAN O., YÜKSEL M., ATACA P., ATILLA E., TOPRAK S. K.
JOURNAL OF CLINICAL ONCOLOGY, 29 May - 02 June 2015
- CLXI. **CML leukemic stem cell CML LSC Its existence in patients who achieved cytogenetic molecular response under treatment of TKI**
İLHAN O., TOPRAK S. K., USLU A., ATILLA E., ARSLAN Ö., ÖZCAN M., ATACA P.
JOURNAL OF CLINICAL ONCOLOGY, 29 May - 02 June 2015
- CLXII. **Autologous Stem Cell Transplantation in Elderly Patients 60 years with Myeloma or Lymphoma Single Center Experience**
gündüz m., ATACA P., ATILLA E., gültekin p., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., İLHAN O., ÖZCAN M.
BONE MARROW TRANSPLANTATION, 22 - 25 March 2015
- CLXIII. **allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Single Centre Experienc**
ŞAHİN U., MERTER M., ATILLA E., TOPÇUOĞLU P., TOPRAK S. K., İLHAN O., YÜKSEL M., ÖZCAN M., CİVRİZ BOZDAĞ S., DALVA K.
BONE MARROW TRANSPLANTATION, 22 - 25 March 2015
- CLXIV. **Different Doses of Anti Thymocyte Globulin ATG in the Conditioning Regimen for Allogeneic Hematopoetic Stem Cell Transplantation**
gültekin p., ateşagaoglu b., MERTER M., TOPÇUOĞLU P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ÖZCAN M., İLHAN O.
BONE MARROW TRANSPLANTATION, 22 - 25 March 2015
- CLXV. **Is it possible to overcome the catastrophic complications of Hematopoietic Stem Cell Transplantation**

HSCT using Plasma Exchange PE A Single Center s Experience

YÜKSEL M., gültekin p., bay m., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., İLHAN O., BEKSAÇ M.

BONE MARROW TRANSPLANTATION, 22 - 25 March 2015

- CLXVI. **upper and lower respiratory tract infections by respiratory viruses in adult recipients of allogeneic hematopoietic stem cell transplantation Allo HSCT Single center**
ŞAHİN D., ATILLA E., USLU A., ATACA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., İLHAN O., GÜRMAN G.
BONE MARROW TRANSPLANTATION, 22 - 25 March 2015
- CLXVII. **Allogeneic Stem Cell Transplantation for Hodgkin and non Hodgkin Lymphoma Single center experience**
ATILLA E., MERTER M., ATACA P., TOPRAK S. K., YÜKSEL M., CİVRİZ BOZDAĞ S., İLHAN O., ÖZCAN M., ARSLAN Ö.
BONE MARROW TRANSPLANTATION, 22 - 25 March 2015
- CLXVIII. **Erythrocytosis following allogeneic hematopoietic stem cell transplantation in six cases**
gültekin p., ATACA P., ATILLA E., TOPRAK S. K., İLHAN O., TOPÇUOĞLU P., USLU A., CİVRİZ BOZDAĞ S., ARSLAN Ö., ÖZCAN M., et al.
BONE MARROW TRANSPLANTATION, 22 - 25 March 2015
- CLXIX. **Effect of pretransplant body mass index on the clinical outcome after allogeneic stem cell transplantation in patients with hematologic malignancies a single center experience**
GÖKMEN A., ender s., YÜKSEL M., İLHAN O., ARSLAN Ö., ÖZCAN M.
BONE MARROW TRANSPLANTATION, 22 - 25 March 2015
- CLXX. **HLA A allele mismatch 7 8 or 9 10 is the second best option after 8 8 or 10 10 matched unrelated donors An analysis on results from Turkish centers**
BEKSAÇ M., TOPÇUOĞLU P., ARAT M., İLHAN O., GÜRMAN G., zafer g.
BONE MARROW TRANSPLANTATION, 22 - 25 March 2015
- CLXXI. **Characterization and MicroRNA Expression Profile Analysis of Mesenchymal Stem Cells Derived From Myelodysplastic Syndrome and Acute myeloid leukemia AML Patients and Comparison with Healthy Controls**
özdoğan h., ATALAY A., İLHAN O.
BONE MARROW TRANSPLANTATION, 22 - 25 March 2015
- CLXXII. **Upper and Lower Respiratory Tract Infections by Respiratory Viruses by Respiratory Viruses in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation Single Center Experience**
ŞAHİN D., ATILLA E., CİVRİZ BOZDAĞ S., ATACA P., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.
41th EBMT Meeting, 22 - 25 March 2015
- CLXXIII. **Generic Bioequivalent Melphalan Has Similar Efficacy and Toxicity but Lower Cost in the Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation 22 25 March 2015 Bone Marrow Transplant 2015 50 S1 S440**
TOPÇUOĞLU P., GÜLTAY D., ÖZTÜRK N., KILIÇ Ö., OKAY M., ERASLAN KARADAĞ Y., ÇINAR H., ATACA P., ATILLA E., CİVRİZ BOZDAĞ S., et al.
41st Annual Meeting of the European Society for Blood and Marrow Transplantation Istanbul, Turkey, 22 - 25 March 2015
- CLXXIV. **Impact of Pre transplant Serum Ferritin on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia**
UĞUR Ş., ERDAL H., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., AKAN H., et al.
41st Annual Meeting of the European Society for Blood and Marrow Transplantation Istanbul, Turkey, 22 - 25 March 2015

Publication: 427

Citation (Scopus): 4092

H-Index (Scopus): 27

Congress and Symposium Activities

17. New Trends In Hematology , Session Moderator, İstanbul, Turkey, 2025
7. Multidisipliner Kök Hücre Öğrenci Kongresi , Invited Speaker, Ankara, Turkey, 2024
- San Diego Sonrası 2024 Biterken Lösemi Lenfoma Miyelom Güncellemesi , Session Moderator, Ankara, Turkey, 2024
66. American Hematoloji Association (ASH) Kongresi , Attendee, California, United States Of America, 2024
1. OMÜKÖK Kök Hücre Kongresi , Session Moderator, Samsun, Turkey, 2024
- KMPH Güncelleme Sempozyumu , Session Moderator, Ordu, Turkey, 2024
19. Ulusal Aferez Kongresi , Session Moderator, İstanbul, Turkey, 2024
- Aydın Hematoloji Günleri , Session Moderator, İzmir, Turkey, 2024
50. Ulusal Hematoloji Kongresi, Session Moderator, Antalya, Turkey, 2024
11. Hematolojik Onkoloji Kongresi , Session Moderator, Lefkoşa, Cyprus (Kkct), 2024
13. Ulusal Geriatrik Hematoloji Kongresi , Session Moderator, Ankara, Turkey, 2024
- Akut Lösemi Çalıştayı , Session Moderator, Sinop, Turkey, 2024
8. Hematolojik İmmünoloji Kongresi , Session Moderator, İzmir, Turkey, 2024
- Uluslararası Katımlı Deneysel Hematoloji Kongresi , Session Moderator, Gaziantep, Turkey, 2024
3. Myeloma Lenfoma-Lösemi Çalıştayı , Session Moderator, Lefkoşa, Cyprus (Kkct), 2024
10. Karadeniz Hematoloji Kongresi , Session Moderator, Samsun, Turkey, 2024
- EHA (Avrupa Hematoloji Derneği), Attendee, Madrid, Spain, 2024
- Ulusal Kan ve Kemik İğili Kongresi, Session Moderator, İstanbul, Turkey, 2024
- Hematoloji Güncellenen Sempozyumu, Session Moderator, Tbilisi, Georgia, 2024